US20170015746A1 - Defined composition gene modified t-cell products - Google Patents

Defined composition gene modified t-cell products Download PDF

Info

Publication number
US20170015746A1
US20170015746A1 US15/302,426 US201515302426A US2017015746A1 US 20170015746 A1 US20170015746 A1 US 20170015746A1 US 201515302426 A US201515302426 A US 201515302426A US 2017015746 A1 US2017015746 A1 US 2017015746A1
Authority
US
United States
Prior art keywords
cells
alternatives
population
cell
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/302,426
Other languages
English (en)
Inventor
Michael C. Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54288361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20170015746(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Priority to US15/302,426 priority Critical patent/US20170015746A1/en
Publication of US20170015746A1 publication Critical patent/US20170015746A1/en
Assigned to Seattle Children's Hospital (dba Seattle Children's Research Institute) reassignment Seattle Children's Hospital (dba Seattle Children's Research Institute) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JENSEN, MICHAEL C
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable

Definitions

  • aspects of the invention concern approaches to make genetically modified T-cells comprising a chimeric antigen receptor.
  • the disclosed methods concern the selection and/or isolation of CD4+ and/or CD8+ T-cells from a mixed T-cell population, which are then activated, genetically modified, and propagated in isolated cultures in the presence of one or more cytokines, which support survival, engraftment and/or proliferation of the cells, as well as, promoting retention of cell surface receptors, such as CD62L, CD28, and/or CD27.
  • the adoptive transfer of human T lymphocytes that are engineered by gene transfer to express chimeric antigen receptors (CARs) specific for molecules present on the surface of tumor cells or malignant B cells has the potential to effectively treat many advanced cancers and malignancies, as well.
  • the administered T-cells that comprise chimeric antigen receptors desirably have a high survival and proliferation rate after transfer to the patient.
  • the T-cells used for therapy are also desirably fit for engraftment. Despite the tremendous effort in the field, the need for additional, effective cellular therapies remains.
  • aspects of the invention described herein include methods of manufacturing genetically modified T-cells comprising a chimeric antigen receptor for human therapy.
  • Alternatives include methods utilizing a selection, enrichment, and/or isolation of CD4+ and/or CD8+ expressing T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed T-cell population.
  • the CD4+ and/or CD8+ expressing T-cells are then activated, genetically modified, and propagated, preferably, in separated, enriched, or isolated cultures in the presence of one or more cytokines, which can be provided exogenously to the T-cells, e.g., in addition to any cytokine that may be produced by the cells or present in media and, which support, promote, induce, or contribute to survival, engraftment and/or proliferation of the cells, as well as, preferably supporting, promoting, inducing, or contributing to the retention of cell surface receptors, such as CD62L, CD28, and/or CD27.
  • cytokines which can be provided exogenously to the T-cells, e.g., in addition to any cytokine that may be produced by the cells or present in media and, which support, promote, induce, or contribute to survival, engraftment and/or proliferation of the cells, as well as, preferably supporting, promoting, inducing, or contributing to the retention of cell
  • Included herein are also methods of treatment, inhibition, amelioration, or elimination of a cancer by administering to a subject in need thereof, one or more types of the genetically engineered T-cells or compositions that comprise the genetically engineered T-cell prepared as described herein.
  • Some aspects of the invention described herein concern methods of making genetically modified T-cells, which have a chimeric antigen receptor.
  • these methods are practiced by separating, isolating, or enriching a CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells so as to generate a separated, isolated, or enriched population of T-cells; stimulating these separated, enriched, or isolated populations of T-cells so as to generate a stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells; transducing the stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells with a vector, wherein the vector encodes a chimeric antigen receptor and a marker sequence, where
  • the CD8+ expressing T-cells and/or CD4+ expressing T-cells can be propagated for at least or equal to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or any time that is within a range of times defined by any two of the aforementioned time points, so as to obtain said genetically modified T-cells, which have a chimeric antigen receptor.
  • the separating or enriching of the CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells is performed by affinity selection for T-cells having an epitope present on CD8 and/or CD4.
  • the separating or enriching of the CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells is performed by flow cytometry. In some alternatives, the separating or enriching of the CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells is performed by immuno-magnetic selection. In some alternatives, the genetically modified CD8+ T-cells and/or CD4+ T-cells comprise at least one receptor that promotes, induces, contributes to, or enhances engraftment fitness.
  • the at least one receptor is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L. In some alternatives, the at least one receptor is CD27, CD28 and/or CD62L.
  • the stimulating of the isolated population of T-cells is performed by contacting the CD8+ and/or CD4+ T-cells with an antibody-bound support, such as a bead or particle.
  • the antibody-bound support comprises anti-TCR, anti-CD2, anti-CD3, anti-CD4 and/or anti-CD28 antibodies. In some alternatives, the antibody-bound support comprises anti-CD3 and/or anti-CD28 antibodies.
  • the vector further comprises a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker.
  • the vector further comprises a sequence encoding a spacer.
  • the spacer comprises an IgG4 hinge.
  • the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector. In some alternatives, the viral vector is a lentivirus vector. In some alternatives, the marker sequence encodes a truncated epidermal growth factor receptor (EGFRt). In some alternatives, the at least one cytokine comprises GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-2, and/or IL-21.
  • EGFRt epidermal growth factor receptor
  • the at least one cytokine comprises IL7, IL-15 and/or IL-21, which can be provided at 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, 0.4 ng/mL, 0.5 ng/mL, 0.6 ng/mL, 0.7 ng/mL, 0.8 ng/mL, 0.9 ng/mL, or 1.0 ng/mL or in an amount that is within a range defined by any two of the aforementioned amounts and/or at 10 U/mL, 20 U/mL, 30 U/mL, 40 U/mL, 50 U/mL, 60 U/mL, 70 U/mL, 80 U/mL, 90 U/mL, or 100 U/mL or in an amount that is within a range defined by any two of the aforementioned amounts.
  • the at least one cytokine comprises IL-2, IL-15 and/or IL-21, wherein the amount of cytokine is provided at 0.5 ng/mL and/or 50 U/mL.
  • the contacting is performed for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or a period of time within a range defined by any two of these values.
  • the method is performed with isolated, purified, enriched or separated CD4+ cells in the absence of, substantially depleted of, or enriched over CD8+ cells.
  • the method is performed with isolated, purified, enriched or separated CD8+ in the absence of, substantially depleted of, or enriched over CD4+ cells.
  • the CD4+ expressing T-cells are propagated for at least 1 day, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or for a period that is within a range defined by any two of the aforementioned time periods.
  • the CD8+ T-cells are propagated at least 1 day, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or for a period that is within a range defined by any two of the aforementioned time periods.
  • the method further comprises removing the antibody-bound support, such as beads or particles.
  • the ligand binding domain of the chimeric antigen receptor comprises an antibody, or a binding portion thereof.
  • the ligand binding domain of the chimeric antigen receptor comprises a single chain variable fragment (scFv), or a binding portion thereof. In some alternatives, the ligand binding domain of the chimeric antigen receptor comprises FMC63, or a binding portion thereof. In some alternatives, the ligand binding domain of the chimeric antigen receptor is specific for CD19. In some alternatives, the method further comprises cryopreserving the genetically modified CD8+ and/or CD4+ T-cells.
  • the separating, enriching, or isolating of the CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells is performed by affinity selection for T-cells having an epitope present on CD8 and/or CD4.
  • the separating, enriching, or isolating of the CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells from a mixed population of T-cells is performed by flow cytometry.
  • the separating, enriching, or isolating of the CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells from a mixed population of T-cells is performed by immuno-magnetic selection.
  • the genetically modified CD8+ expressing T-cells and/or CD4+ expressing T-cells comprise at least one receptor that promotes, induces, or contributes to engraftment fitness.
  • the at least one receptor that promotes, induces, or contributes to engraftment fitness is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L.
  • the at least one receptor that promotes, induces, or contributes to engraftment fitness is CD27, CD28 and/or CD62L.
  • the stimulating of the isolated, enriched, or separated population of T-cells is performed by contacting the CD8+ and/or CD4+ expressing T-cells with an antibody-bound support, such as a bead or particle.
  • the antibody-bound support comprises anti-TCR, anti-CD2, anti-CD3, anti-CD4 and/or anti-CD28 antibodies.
  • the antibody-bound support comprises anti-CD3 and/or anti-CD28 antibodies.
  • the vector further comprises a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the vector further comprises a sequence encoding a spacer, which in some alternatives may comprise an IgG4 hinge.
  • the vector is a viral vector or a mini-circle.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector.
  • the viral vector is a lentivirus vector.
  • the marker sequence encodes a truncated epidermal growth factor receptor (EGFRt).
  • the at least one cytokine that is utilized comprises GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-2, and/or IL-21 and said cytokine is provided exogenously to the T-cells e.g., in addition to any cytokine that may be produced by the cells or present in media.
  • the at least one cytokine comprises IL-7, IL-15 and/or IL-21. In many of the aforementioned alternatives, the at least one cytokine comprises IL-2, IL-15 and/or IL-21. In preferred alternatives, the contacting period is performed for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or a period of time within a range defined by any two of these time points.
  • the methods are performed with isolated, separated, or enriched populations of CD4+ expressing T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, in the absence of or having a reduced amount CD8+ expressing T-cells, as compared to a native population of unseparated, non-enriched, or non-isolated population of T-cells.
  • isolated, separated, or enriched populations of CD4+ expressing T-cells such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, in the absence of or having a reduced amount CD8+ expressing T-cells, as compared to a native population of unseparated, non-enriched, or non-isolated population of T-cells.
  • these methods are performed with isolated, separated, or enriched populations of CD8+ expressing T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, in the absence of or having a reduced amount of CD4+ expressing T-cells, as compared to a native population of unseparated, non-enriched, or non-isolated population of T-cells.
  • isolated, separated, or enriched populations of CD8+ expressing T-cells such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, in the absence of or having a reduced amount of CD4+ expressing T-cells, as compared to a native population of unseparated, non-enriched, or non-isolated population of T-cells.
  • the CD4+ expressing T-cells are propagated for at least 1 day, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or any time that is within a range of times defined by any two of the aforementioned time points.
  • the CD8+ expressing T-cells are propagated for at least 1 day, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or any time that is within a range of times defined by any two of the aforementioned time points.
  • the methods further comprise removing the antibody-bound support, such as beads or particles.
  • the ligand binding domain of the chimeric antigen receptor comprises an antibody, or a binding portion thereof.
  • the ligand binding domain of the chimeric antigen receptor comprises a single chain variable fragment (scFv), or a binding portion thereof.
  • the ligand binding domain of the chimeric antigen receptor comprises FMC63, or a binding portion thereof, such as is available in U.S. Pat. No. 7,446,179, herein expressly incorporated by reference in its entirety.
  • the ligand binding domain of the chimeric antigen receptor is specific for CD19.
  • the method further comprises cryopreserving the genetically modified CD8+ and/or CD4+ T-cells.
  • Additional aspects of the invention concern a population of genetically modified T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, comprising a plurality of affinity selected CD8+ and/or CD4+ expressing T-cells, in an enriched form, such as enriched from, in the absence of, or isolated from CD8 ⁇ and/or CD4 ⁇ expressing T-cells, wherein said plurality of affinity selected CD8+ and/or CD4+ expressing T-cells have stimulated CD2, CD3, CD4 and/or CD28 receptors, wherein said plurality of affinity selected or enriched CD8+ and/or CD4+ expressing T-cells further comprise a gene encoding a chimeric antigen receptor and a gene encoding a cell surface selectable marker and, wherein said plurality of affinity selected or enriched CD8+ and/or CD4+ expressing T-cells have been re-stimulated with at least one cytokine, which can
  • said plurality of affinity selected CD8+ and/or CD4+ expressing T-cells further comprise at least one receptor that promotes, induces, or contributes to engraftment fitness.
  • the at least one receptor that promotes, induces, improves, or contributes to engraftment fitness is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L.
  • the at least one receptor that promotes, induces, improves, or contributes to engraftment fitness is CD27, CD28 and/or CD62L.
  • the plurality of affinity selected CD8+ and/or CD4+ expressing T-cells further comprises a vector having a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the population of genetically modified T-cells comprises a plurality of affinity selected CD8+ and/or CD4+ T-cells, absence of, substantially depleted of, or enriched over CD8 ⁇ and/or CD4 ⁇ T-cells, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells have stimulated CD2, CD3, CD4 and/or CD28 receptors, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise a gene encoding a chimeric antigen receptor and a cell surface selectable marker and, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells have been re-stimulated with at least one cytokine.
  • said plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise at least one receptor that promotes, enhances, improves or contributes to engraftment fitness.
  • the at least one receptor that promotes, enhances, improves or contributes to engraftment fitness is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L.
  • the at least one receptor that promotes, enhances, improves or contributes to engraftment fitness is CD27, CD28 and/or CD62L.
  • the plurality of affinity selected CD8+ and/or CD4+ T-cells further comprises a vector having a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker.
  • the vector further comprises a sequence encoding a spacer.
  • the spacer comprises an IgG4 hinge.
  • the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector. In some alternatives, the viral vector is a lentivirus vector.
  • the cell surface selectable marker encodes for a truncated epidermal growth factor receptor (EGFRt).
  • the ligand binding domain comprises an antibody, or a binding portion thereof. In some alternatives, the ligand binding domain comprises a single chain variable fragment (scFv), or a binding portion thereof. In some alternatives, the ligand binding domain comprises FMC63, or a binding portion thereof. In some alternatives, the ligand binding domain is specific for CD19.
  • the population comprises isolated, purified, separated or enriched CD8+ T-cells in the absence of, substantially depleted of, or enriched over CD4+ T-cells. In some alternatives, the population comprises isolated, purified, separated or enriched CD4+ T-cells in the absence of, substantially depleted of, or enriched over CD8+ T-cells.
  • the T cell is a precursor T cell. In some alternatives, the precursor T cell is a hematopoietic stem cell.
  • the vector further comprises a sequence encoding a spacer, such as a spacer that comprises an IgG4 hinge. In some alternatives, the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector.
  • the viral vector is a lentivirus vector or a mini-circle.
  • the cell surface selectable marker encodes for a truncated epidermal growth factor receptor (EGFRt).
  • the ligand binding domain comprises an antibody, or a binding portion thereof.
  • the ligand binding domain comprises a single chain variable fragment (scFv), or a binding portion thereof.
  • the ligand binding domain comprises FMC63, or a binding portion thereof, such as is available in U.S. Pat. No. 7,446,179, herein expressly incorporated by reference in its entirety.
  • the ligand binding domain is specific for CD19.
  • the population of genetically modified T-cells such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, comprises isolated CD8+ expressing T-cells in the absence of or having a reduced amount of CD4+ expressing T-cells, as compared to a native population of unseparated, non-enriched, or non-isolated population of T-cells.
  • the population of genetically modified T-cells comprises isolated CD4+ expressing T-cells in the absence of or having a reduced amount of CD8+ expressing T-cells, as compared to a native population of unseparated, non-enriched, or non-isolated population of T-cells.
  • compositions or product combination for human therapy comprising a pharmaceutical excipient; and at least one population of the genetically modified T-cells, as set forth in the preceding paragraph.
  • the composition or product combination comprises a population of genetically modified CD8+ expressing T-cells.
  • the composition or product combination comprises a population of genetically modified CD4+ expressing T-cells.
  • the composition or product combination comprises the population of genetically modified CD8+ expressing T-cells, as set forth above, and the population of genetically modified CD4+ expressing T-cells, as set forth above, in a mixed population or co-administered in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10:1 ratio or a ratio that is within a range defined by any two of the aforementioned ratios.
  • Additional aspects of the invention concern methods of treating, inhibiting, or ameliorating a disease in a subject in need thereof comprising administering to the subject at least one composition or product combination set forth above.
  • the methods comprise administering a composition or product combination comprising CD4+ expressing T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, in advance or prior to administration of the CD8+ expressing T-cells and in other alternatives, the CD8+ expressing cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, are administered before the CD4+ expressing T-cells.
  • the subject is identified or selected to receive an anti-cancer therapy.
  • the approach also involves measuring or evaluating an inhibition of a disease.
  • the approach also involves providing said subject an additional anti-cancer therapy before, during, or after administration of a composition or product combination set forth above.
  • a composition or product combination is administered to said subject by adoptive cell transfer. In some alternatives, a composition or product combination are administered to said subject after said subject has received another form of anti-cancer therapy.
  • the subject is suffering from leukemia.
  • the subject has recurrent and/or chemotherapy refractory CD19+ childhood acute lymphoblastic leukemia (ALL).
  • ALL acute lymphoblastic leukemia
  • the subject has recurrent and/or chemotherapy refractory CD19+ acute lymphoblastic leukemia (ALL).
  • ALL recurrent and/or chemotherapy refractory CD19+ acute lymphoblastic leukemia
  • the subject is suffering from an autoimmune disease.
  • the subject is suffering from a post-HSCT relapse.
  • a method of making genetically modified T-cells, which have a chimeric antigen receptor comprising:
  • separating or enriching a CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells so as to generate a separated or enriched population of T-cells;
  • transducing the stimulated population of CD8+ T-cells and/or CD4+ T-cells with a vector wherein the vector encodes a chimeric antigen receptor and a marker sequence, wherein said marker sequence encodes a cell surface selectable marker, so as to generate a transduced population of CD8+ T-cells and/or CD4+ T-cells;
  • contacting the transduced population of CD8+ T-cells and/or CD4+ T-cells with at least one cytokine which can be provided exogenously to the T-cells, e.g., in addition to any cytokine that may be produced by the cells or present in media, such as for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or for a period that is within a range defined by any two of the aforementioned time periods, so as to generate a transduced, cytokine-stimulated population of CD8+ T-cells and/or CD4+ T-cells;
  • CD8+ T-cells and/or CD4+ T-cells comprise at least one receptor that promotes, induces, contributes to, or enhances engraftment fitness.
  • antibody-bound support comprises anti-TCR, anti-CD2, anti-CD3, anti-CD4 and/or anti-CD28 antibodies.
  • the vector further comprises a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector.
  • the at least one cytokine comprises GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-2 and/or IL-21.
  • the at least one cytokine comprises IL7, IL-15 and/or IL-21, which can be provided at 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, 0.4 ng/mL, 0.5 ng/mL, 0.6 ng/mL, 0.7 ng/mL, 0.8 ng/mL, 0.9 ng/mL, or 1.0 ng/mL or in an amount that is within a range defined by any two of the aforementioned amounts and/or at 10 U/mL, 20 U/mL, 30 U/mL, 40 U/mL, 50 U/mL, 60 U/mL, 70 U/mL, 80 U/mL, 90 U/mL, or 100 U/mL or in an amount that is within a range defined by any two of the aforementioned amounts.
  • a population of genetically modified T-cells comprising:
  • the population of genetically modified T-cells of alternative 33 or 34, wherein the at least one receptor that promotes, enhances, improves or contributes to engraftment fitness is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L.
  • the population of genetically modified T-cells of alternative 34 or 35, wherein the at least one receptor that promotes, enhances, improves or contributes to engraftment fitness is CD27, CD28 and/or CD62L.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • composition or product combination for human therapy comprising:
  • composition or product combination of alternative 51 wherein the composition or product combination comprises the population of genetically modified T-cells of alternative 49.
  • composition or product combination of alternative 47, wherein the composition or product combination comprises the population of genetically modified T-cells of alternative 50.
  • composition or product combination of alternative 47 wherein the composition or product combination comprises the population of genetically modified T-cells of alternative 49 and the population of genetically modified T-cells of alternative 50, mixed or co-administered in a 1:1 ratio.
  • a method of treating, inhibiting, or ameliorating a disease in a subject in need thereof comprising:
  • the method comprises administering the composition or product combination of alternative 54, such as by an approach, wherein the CD8+ expressing T-cells are administered in advance of the CD4+ expressing T-cells, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or 60 minutes before the CD4+ T-cells are administered or a time period that is within a range defined by any two of the aforementioned times.
  • ALL acute lymphoblastic leukemia
  • FIG. 1A shows the absolute number of anti-CD19 CAR bearing T-cells in 11 patients following adoptive transfer of the CAR bearing T-cells from Day 0 to Day 65.
  • FIG. 1B shows the absolute number of anti-CD19 CAR bearing T-cells following three doses of treatment.
  • FIG. 2A shows the persistence of anti-CD19 CAR bearing T-cells in peripheral blood of patients following adoptive transfer of the CAR bearing T-cells from Day 0 to Day 65.
  • FIG. 2B shows the persistence of anti-CD19 car bearing T-cells following three doses of treatment.
  • FIG. 3A shows the persistence of anti-CD19 CAR bearing T-cells in bone marrow of patients following adoptive transfer of the CAR bearing T-cells from Day 0 to Day 65.
  • FIG. 3B shows the persistence of anti-CD19 CAR bearing T-cells in bone marrow patients following three doses of treatment.
  • FIG. 4 shows the percent acute lymphoblastic leukemia (ALL) in patient X following three doses.
  • FIG. 5 shows a table of the patient characteristics that were used in the studies.
  • FIG. 6 shows the development of CNS lymphoma, as related to disease and dosage. As shown, two bar graphs indicate the number of patients subjected to the treatment comprising anti-CD19 CAR bearing T-cells and their severity of disease following 3 treatments.
  • FIG. 7 shows grade 4 encephalopathy in an abnormal MRI of a patient suffering from ALL.
  • the first panel indicates the results following treatment using anti-CD19 CAR bearing T-cells.
  • FIG. 8 shows acute Skin Graft-versus-host disease (GVHD) following treatment with anti-CD19 CAR bearing T-cells.
  • GVHD Skin Graft-versus-host disease
  • panel A S03 developed de novo grade 2 acute skin GVHD d17 post CAR T-cell engraftment.
  • panel B a skin biopsy revealed that only 9% of skin localized T-cells marked EGFRt+ while 79% of circulating T-cells marked EGFRt+.
  • peripheral blood at the same time showed the majority of the T-cells were CAR+.
  • This subject was treated with a 2 week course of 1 mg/kg of prednisone, followed by a rapid taper over a six week period and resolution of the GVHD. Despite the prednisone, the subject has ongoing persistent CAR+ T-cells.
  • FIG. 9 shows a table of patients experiencing Ig or TCR as a marker of minimal residual disease (MRD) following treatment using anti-CD19 CAR bearing T-cells.
  • MRD minimal residual disease
  • FIG. 10 shows a table of patient profiles after allogeneic hematopoietic stem cell transplantation of anti-CD19CAR T-cells.
  • FIG. 11 shows the FACS scatter analysis of the cells isolated from the peripheral blood and CSF following hematopoietic stem cell transplantation (HSCT) of anti-CD19 CAR T-cells.
  • HSCT hematopoietic stem cell transplantation
  • FIG. 12 shows the tumor burden vs the response after three doses of hematopoietic stem cell transplantation of anti-CD19 CAR T-cells.
  • FIG. 13 shows the remission duration of patients following three doses of hematopoietic stem cell transplantation.
  • FIG. 14 shows the tumor burden vs the response after two doses of hematopoietic stem cell transplantation of anti-CD19CAR T-cells at day 7.
  • FIG. 15 shows the magnitude and duration of CAR/EGFRt+ T-cell persistence in a patient after three doses of hematopoietic stem cell transplantation of anti-CD19 CAR T-cells.
  • FIG. 16 shows the duration of B cell aplasia after three doses of hematopoietic stem cell transplantation of anti-CD19 CAR T-cells.
  • FIG. 17 shows the CRS profile of a patient after three doses of hematopoietic stem cell transplantation of anti-CD19 CAR T-cells.
  • FIG. 18 shows two flow diagrams illustrating the manufacturing of genetically modified T-cells. As depicted, for the initial expansion methodology bulk processing was not always initiated immediately. A portion of the apheresis product was always taken for Ficoll processing. If no bulk cultures were to be initiated then that product separated by Ficoll was cryopreserved.
  • FIG. 19 shows a flow diagram of comparisons of different methods of making genetically modified T-cells that have chimeric antigen receptors.
  • FIG. 20 shows the initial comparisons in cell growth using different concentrations of cells in the starter culture.
  • PD0064 are the PD0063 donor which are enriched CD8+ expressing T-cells were used to test starting cell density in T25 flask on initiation. The experiments tested two cell densities and both showed greater viability and expansion when the volume was increased early during the experiment.
  • FIG. 21 shows an initiation comparison of cell growth. This was the full scale data used to transition to the update manufacturing process currently being used.
  • FIG. 22 shows a flow diagram illustrating the variations of cocktails of cytokines that were used to test CD4+ and CD8+ expressing T-cells for growth.
  • FIGS. 23A-F illustrate the comparison of cytokines that were tested during the growth of CD4+ and CD8+ expressing T-cells.
  • FIGS. 24A-F illustrate the comparison of cytokines that were tested during the growth of CD4+ and CD8+ expressing T-cells.
  • FIGS. 25A-B shows a cytokine comparisons for cell growth.
  • PD0059 donor sample the same cytokine testing experiment was performed as in PD0051 except testing a new CD4 and CD8 donor (PD0057).
  • FIG. 26 shows a flow diagram illustrating the initial expansion methodology and the current expansion methodology derived from the experimentation of testing different cytokine mixtures.
  • FIG. 27 shows expansion comparisons of samples PD0080, PD084 and PD0085. These experiments were repeats of the “early expansion” methodology.
  • FIG. 28 shows the tests on PD0044 for producing the genetically modified cells.
  • PLAT-02 Phase I and Phase II trial
  • pre-qual from cryopreserved selected cells were used.
  • FIG. 29 shows the tests on PD0046 for producing the genetically modified cells from the scale up of PLAT-02 “Qual run #1”.
  • FIG. 30 shows the tests on PD0063 for producing the genetically modified cells. From the scale up or PLAT-02 “Qual run #2”. Growth curves show TNC from both V-197 bags of cells together. Bead removal and EGFRt enrichment occurred afterward. D+14 for CD4+ expressing T-cells and D+15 for CD8+ expressing T-cells. CD8+ expressing T-cells grown in IL-2 (50 U/mL)/IL-15 (0.5 ng/mL), CD4+ expressing T-cells grown in IL-7 (5 ng/mL)/IL-15 (0.5 ng/mL). Bead removal and EGFRt enrichment occurred at D12 for CD4+ expressing T-cells and D13 for CD8+ expressing T-cells.
  • FIGS. 31A-B show the expansion of cells from bulk PBMC cultures when grown in the presence of cytokines. As shown, CD4+ expressing T-cells ( ⁇ ) were grown in the presence of IL-2 and IL-15. CD8+ expressing T-cells ( ⁇ ) were grown in the presence of IL-7 and IL-15.
  • FIGS. 32A-B show the expansion of enriched CD8+ and CD4+ expressing T-cells in cytokine mixtures.
  • enriched CD8+ expressing T-cells were expanded in the presence of IL-2 and IL-15.
  • enriched CD4+ expressing T-cells were expanded in the presence of IL-7 and IL-15 for over 20 days.
  • FIG. 33 shows expansion of enriched CD4+ and CD8+ expressing T-cells using an earlier methodology as shown in the flow chart of FIG. 18 . Shown are experiments of cells in sample 14602-S01, 14602-S02, and 14602-S03/14602-S03-02.
  • FIG. 34 shows expansion of enriched CD4+ and CD8+ expressing T-cells using an earlier methodology as shown in the flow chart of FIG. 18 . Shown are experiments of cells in sample 14602-S04/14602-S04-02, 14602-S05, 14602-S06 and 14602-S06-2/14602-S06-04.
  • FIG. 35 shows the expansion of enriched CD4+ and CD8+ expressing T-cells using the “Early Expansion methodology as shown in the flow chart of FIG. 18 . Shown are experiments of cells in sample 14602-S07, 14602-S08, and 14602-S09.
  • FIG. 36 shows the expansion of cells in samples 14602-S10, 14602-S11, 14602-S12, and 14602-S13.
  • FIG. 37 shows the expansions of cells in samples 14602-S14, 14602-S15, and 14602-S16.
  • FIG. 38 shows the enriched CD4+ and CD8+ expressing T-cells extended phenotypes after cell expansion.
  • FIGS. 39A-B shows the survival of a mouse injected with cells from the sample PD00044 and PD00046.
  • PD00046 cells were noted for having expression of engraftment fitness markers (CD27, CD28, CD127, and CD62L).
  • FIG. 40 shows the average tumor progression in mice treated with cells from the PD0044 and PD0046 cell batches.
  • FIG. 41 shows the experimental set up of testing tumor progression in mice treated with T-cells that are manufactured for engraftment fitness.
  • FIG. 42 shows a comparison between CD4+ and CD8+ expressing T-cells from the samples PD0051 and PD00055 on the day of administration into animals and the cytokine growth conditions.
  • FIG. 43 shows a comparison of the three groups of mice that were treated with PBS, PD0051 (normal expansion cells) and PD00055 (cells expanded in the presence of cytokine combinations)
  • FIG. 44 shows the T-cell persistence in peripheral blood of the mice by detection of the EGFRt CAR marker.
  • FIG. 45 shows the experimental set up for testing three groups of mice in order to determine an in vivo difference in killing ability between cells that have been grown in various cytokine conditions in vitro with repeat antigen encounters.
  • FIG. 46 shows the tumor progression of PD0051 and PD0055 treated mice following treatment from day 0 to day 120.
  • FIG. 47 shows PD0051 and PD0055 cells challenged with repeat antigen exposure.
  • FIG. 48 shows JME13-29 repeated Raji Tumor challenge of “normal expansion cells” versus T-cells pulsed with cytokine combinations.
  • FIG. 49 shows the experimental set up to determine if there is an in vivo difference in killing ability between cells that have been grown under the same conditions as PLAT-01 (Phase I clinical trial) and PLAT-02 (Phase I and Phase II clinical trial), as well as, “in between” protocols.
  • FIG. 50 shows a table that indicates the cell products and the levels of EGFRt from the CD8+ and CD4+ expressing T-cells.
  • FIG. 51 shows the average tumor progression after treatment with T-cells at specific dose titrations.
  • FIG. 52 shows the PLAT comparisons within dosing groups of T-cell treatments.
  • FIGS. 53A-E show the comparison of T-cells from the products of PLAT-1.00, PLAT-1.33, PLAT-1.67 and PLAT-2.00 at similar dosing concentrations.
  • the figure illustrates the tumor progression of individual animals. The start of each row shows the grouped for each PLAT group with the various dose titrations, followed by the individual groups teased out.
  • FIG. 54 shows the dose titration survival of mice treated with T-cells from the products of PLAT-1.00, PLAT-1.33, PLAT-1.67 and PLAT-2.00. The figure illustrates the PLAT comparison within dosing groups of cell treatments.
  • FIG. 55 shows the PLAT comparison of survival curves. The figure illustrates the average tumor progression after treatment with T-cells at specific doses.
  • FIG. 56 shows the survival of the mice in response to T-cell treatment in which the T-cells were grown in normal expansion methods or grown in the presence of cytokines. The figure also shows if the mice developed xenoGraft Host disease after T-cell treatment
  • FIG. 57 shows the survival of the mice in response to T-cell treatment in which the T-cells were grown in normal expansion methods or grown in the presence of cytokines. The figure also shows if the mice developed xenoGraft Host disease after T-cell treatment
  • FIGS. 58A-C show the survival of the mice in response to T-cell treatment in which the T-cells were grown in normal expansion methods or grown in the presence of cytokines. The figures also show if the mice developed xenoGraft Host disease after T-cell treatment
  • FIGS. 59A-H show the survival of the mice in response to T-cell treatment in which the T-cells were grown in normal expansion methods or grown in the presence of cytokines. The figures also show if the mice developed xenoGraft Host disease after T-cell treatment
  • FIGS. 60A-D show the survival of the mice in response to T-cell treatment in which the T-cells were grown in normal expansion methods or grown in the presence of cytokines. The figures also show if the mice developed xenoGraft Host disease after T-cell treatment.
  • FIG. 61 shows a table of JME14-03 Group N, at Day 51 post-T cell treatment at 51 days and at 90 days.
  • nucleic acid or “nucleic acid molecule” refers to polynucleotides or oligonucleotides such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, exonuclease action, and by synthetic generation.
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • PCR polymerase chain reaction
  • Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both.
  • Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties.
  • Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters.
  • the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs.
  • modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes.
  • Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like.
  • nucleic acid molecule also includes so-called “peptide nucleic acids,” which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded.
  • Genetically modify refers to a process for modifying an organism or a cell such as a bacterium, T-cell, bacterial cell, eukaryotic cell, insect, plant or mammal with genetic material, such as nucleic acid, that has been altered using genetic engineering techniques.
  • nucleic acid such as DNA can be inserted in the host genome by first isolating and copying the genetic material of interest using molecular cloning methods to generate a DNA sequence, or by synthesizing the DNA, and then inserting this construct into the host organism.
  • Genes can also be removed, or “knocked out”, using a nuclease.
  • Gene targeting is a different technique that uses homologous recombination to change an endogenous gene, and can be used to delete a gene, remove exons, add a gene, or introduce point mutations.
  • Transduction refers to methods of transferring genetic material, such as, for example, DNA or RNA, to a cell by way of a vector. Common techniques use viral vectors, electroporation, and chemical reagents to increase cell permeability. The DNA can be transferred by a virus, or via a viral vector. As described herein, methods are provided for modifying immune CD4+ and/or CD8+ T-cells. In order to achieve high expression of therapeutic genes and/or increase the amount of chimeric antigen receptors on a cell surface, for example, T-cells can be transduced with genetic material encoding a chimeric antigen receptor. T-cells can be genetically modified using a virus. Viruses commonly used for gene therapy are adenovirus, adeno-associated virus (AAV), retroviruses and lentiviruses.
  • AAV adeno-associated virus
  • the viral vectors used for transduction can include virus vectors derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentiviral vectors, and retroviruses.
  • virus vectors derived from simian virus 40 can include virus vectors derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentiviral vectors, and retroviruses.
  • retroviral and lentiviral vectors can provide a highly efficient method for gene transfer in eukaryotic cells.
  • Retroviral and lentiviral vectors provide highly efficient methods for gene transfer into T-cells.
  • retroviral or lentiviral integration takes place in a controlled fashion and results in the stable integration of one or a few copies of the new genetic information per cell.
  • an “expression vector” or a vector, as described herein, is a nucleic acid molecule encoding a gene that is expressed in a host-cell.
  • an expression vector comprises a transcription promoter, a gene, and a transcription terminator. Gene expression is usually placed under the control of a promoter, and such a gene is said to be “operably linked to” the promoter.
  • a regulatory element and a core promoter are operably linked if the regulatory element modulates the activity of the core promoter.
  • the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector.
  • the viral vector is a lentivirus vector.
  • the vector encoding the chimeric antigen receptor comprises a sequence encoding a leader sequence.
  • a “ligand” as described herein refers to a small molecule that can form a complex with another molecule or biomolecule for a biological purpose such as, for example, signal triggering. Binding can occur through intermolecular forces, for example ionic bonds, hydrogen bonds, and van der walls interactions. Ligand binding to a receptor protein can alter the three dimensional structure and determine its functional state.
  • ligands can include substrates, proteins, small molecules, inhibitors, activators and neurotransmitters.
  • the strength of binding of a ligand is referred to as the binding affinity and can be determined by direct interactions and solvent effects.
  • a ligand can be bound by a “ligand binding domain.”
  • a ligand binding domain can refer to a conserved sequence in a structure that can bind a specific ligand.
  • a ligand binding domain can be a specific protein domain that is specific for a ligand or ligands.
  • Specific can refer to the characteristic of a ligand for the binding partner or alternatively, the binding partner for the ligand, and can include complementary shape, charge and hydrophobic specificity for binding. Specificity for binding can include stereospecificity, regioselectivity and chemoselectivity.
  • a “signaling domain,” also known as a “Co-stimulatory domain” is an intracellular or cytoplasmic domain of a protein or a receptor protein that interacts with the interior of the cells and functions by relaying a signal.
  • the portion of the protein that resides in the intracellular portion of the cell is also referred to as the “endodomain.” This interaction can occur through the intracellular domain communicating via specific protein-protein or protein-ligand interactions with an effector molecule or an effector protein, which in turn can send the signal along a signal chain to its destination.
  • the signaling or co-stimulatory domain also refers to a signaling moiety that provides to T-cells a signal which, in addition to the primary signal provided by for instance the CD3 zeta chain of the TCR/CD3 complex, mediates a T-cell response, such as, for example, an immune response, activation, proliferation, differentiation, cytokine secretion, cytolytic activity, perforin and/or granzyme activity and the like.
  • a signaling or co-stimulatory domain can include all or a portion of, but is not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and/or a ligand that specifically binds with CD83.
  • LFA-1 lymphocyte function-associated antigen-1
  • Selectable marker sequence is a gene introduced into a vector or a cell that confers a trait for artificial selection.
  • a selectable marker sequence or marker sequence can be a screenable marker to allow a researcher to distinguish between wanted and unwanted cells, or to enrich for a specific cell type.
  • a vector is provided wherein the vector encodes a chimeric antigen receptor comprising a marker sequence, wherein said marker sequence encodes a cell surface selectable marker.
  • a method of making genetically modified T-cells, which have a chimeric antigen receptor comprises separating, isolating or enriching a CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells so as to generate an isolated, separated, or enriched population of T-cells, stimulating the isolated, separated or enriched population of T-cells so as to generate a stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells, transducing the stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells with a vector, wherein the vector encodes a chimeric antigen receptor and a marker sequence, wherein said marker sequence encodes a cell
  • the vector further comprises a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the vector further comprises a sequence encoding a spacer.
  • the spacer comprises an IgG4 hinge.
  • the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector. In some alternatives of the method, the viral vector is a lentivirus vector. In some alternatives of the method, the marker sequence encodes a truncated epidermal growth factor receptor (EGFRt). In some alternatives of the method, the ligand binding domain of the chimeric antigen receptor comprises an antibody, or a binding portion thereof. In some alternatives of the method, the ligand binding domain of the chimeric antigen receptor comprises a single chain variable fragment (scFv), or a binding portion thereof.
  • scFv single chain variable fragment
  • the ligand binding domain of the chimeric antigen receptor comprises FMC63, or a binding portion thereof. In some alternatives of the method, the ligand binding domain of the chimeric antigen receptor is specific for CD19. In some alternatives of the method, the vector comprises a sequence encoding a maker sequence. In some of these alternatives, the marker sequence is a truncated epidermal growth factor receptor (EGFRt).
  • EGFRt epidermal growth factor receptor
  • Codon optimization refers to the design process of altering codons to codons known to increase maximum protein expression efficiency.
  • codon optimization for expression in human is described, wherein codon optimization can be performed by using algorithms that are known to those skilled in the art so as to create synthetic genetic transcripts optimized for high mRNA and protein yield in humans.
  • Programs containing algorithms for codon optimization in humans are readily available. Such programs can include, for example, OptimumGeneTM or GeneGPS® algorithms.
  • human codon optimized sequences can be obtained commercially, for example, from Integrated DNA Technologies.
  • a method of making genetically modified T-cells, which have a chimeric antigen receptor comprises separating, isolating, or enriching a CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells so as to generate an isolated, separated, or enriched population of T-cells, stimulating the isolated, separated, or enriched population of T-cells so as to generate a stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells, transducing the stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells with a vector, wherein the vector encodes a chimeric antigen receptor and a marker sequence, wherein said marker sequence encodes
  • the vector further comprises a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the sequences of the vector are codon optimized for expression in humans.
  • the sequences of the vector are optimized to have selected codons specifically for maximal protein expression in human cells, which can increase the concentration of proteins or CARs of a T-cell.
  • optimization can also be performed to reduce the occurrence of secondary structure in a polynucleotide.
  • optimization of the sequences in the vector can also be performed to reduce the total GC/AT ratio. Strict codon optimization can lead to unwanted secondary structure or an undesirably high GC content that leads to secondary structure. As such, the secondary structures affect transcriptional efficiency. Programs such as GeneOptimizer can be used after codon usage optimization, for secondary structure avoidance and GC content optimization. These additional programs can be used for further optimization and troubleshooting after an initial codon optimization to limit secondary structures that can occur after the first round of optimization. Alternative programs for optimization are readily available.
  • the vector comprises sequences that are optimized for secondary structure avoidance and/or the sequences are optimized to reduce the total GC/AT ratio and/or the sequences are optimized for expression in humans.
  • Marker domains can also provide important aspects to alternatives described herein. Utilization of a marker domain on the cell surface can allow for transduced lymphocyte ablation in the event of a toxic event associated with administration or the presence of transduced T-cells.
  • a marker domain on the cell surface can allow for transduced lymphocyte ablation in the event of a toxic event associated with administration or the presence of transduced T-cells.
  • an EGFRt marker sequence full length antibodies to EGFR can be utilized to bind to cells expressing the EGFR and kill them via antibody dependent cell mediated cytotoxicity (ADCC).
  • an antibody specific for a marker domain can be linked to a cytotoxic agent, such as a radionuclide or a toxin, which results in a therapeutic capable of ablation or killing of the transduced cells in vivo.
  • a marker sequence is provided for enrichment and cell selection.
  • an EGFRt marker sequence is used in a purification and enrichment method allowing for immunomagnetic selection against the
  • a “spacer” as described herein can refer to a polypeptide chain that can range in length from a length of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112,
  • a spacer can comprise any 20 amino acids, for example, in any order to create a desirable length of polypeptide chain in a chimeric antigen receptor, which includes the amino acids arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, glycine, proline, alanine, valine, isoleucine, methionine, phenylalanine, tyrosine and/or tryptophan.
  • a spacer sequence can be a linker between the scFv and the transmembrane domain of the chimeric antigen receptor.
  • the vector further comprises a sequence encoding a spacer.
  • the spacer comprises a sequence with a length of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101,
  • IgG4 hinge refers to the polypeptide domains that are between the heavy chain and the light chains of the IgG4 antibody.
  • a method of making genetically modified T-cells, which have a chimeric antigen receptor comprises separating, enriching, or isolating a CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells so as to generate an isolated, separated, or enriched population of T-cells, stimulating the isolated, separated, or enriched population of T-cells so as to generate a stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells, transducing the stimulated population of CD8+ expressing T-cells and/or CD4+
  • the vector further comprises a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker.
  • the vector further comprises a sequence encoding a spacer.
  • the spacer comprises a hinge region of a human antibody.
  • the spacer comprises an IgG4 hinge.
  • the IgG4 hinge region is a modified IgG4 hinge.
  • a “modified IgG4 hinge” as described herein can refer to a hinge region that can have at least 90%, 92%, 95%, or 100% sequence identity or a sequence identity within a range defined by any two of the aforementioned percentages, with a hinge region amino acid sequence as set forth in SEQ ID NO: 1 (SEQ ID NO: 1; ESKYGPPCPPCP), SEQ ID NO: 2 (SEQ ID NO: 2; YGPPCPPCP), SEQ ID NO: 3 (SEQ ID NO: 3; KYGPPCPPCP), or SEQ ID NO: 4 (SEQ ID NO: 4; EVVKYGPPCPPCP).
  • any one or more of these sequences can be codon optimized for expression in humans and any one or more of these sequences can be optimized to reduce secondary structure or GC/AT ratio and any one or more of these sequences can be consensus sequences generated from at least two isotype genes.
  • a “transmembrane domain” is a region of a protein that is hydrophobic that can reside in the bilayer of a cell to anchor a protein that is embedded to the biological membrane. Without being limiting, the topology of the transmembrane domain can be a transmembrane alpha helix.
  • the vector comprises a sequence encoding a transmembrane domain.
  • the transmembrane domain comprises a CD28 transmembrane sequence or a fragment thereof that is a length of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 amino acids or a length within a range defined by any two of the aforementioned lengths.
  • the CD28 transmembrane sequence or fragment thereof comprise 28 amino acids in length.
  • the transmembrane domain comprises the sequence set forth in SEQ ID NO: 5 (SEQ ID NO: 5; MFWVLVVVGGVLACYSLLVTVAFIIFWV).
  • a “signaling domain,” also known as a “Co-stimulatory domain” is an intracellular or cytoplasmic domain of a protein or a receptor protein that interacts with the interior of the cells and functions by relaying a signal.
  • the portion of the protein that resides in the intracellular portion of the cell is also referred to as the “endodomain.” This interaction can occur through the intracellular domain communicating via specific protein-protein or protein-ligand interactions with an effector molecule or an effector protein, which in turn can send the signal along a signal chain to its destination.
  • the signaling or co-stimulatory domain also refers to a signaling moiety that provides to T-cells a signal which, in addition to the primary signal provided by for instance the CD3 zeta chain of the TCR/CD3 complex, mediates a T-cell response, such as, for example, an immune response, activation, proliferation, differentiation, cytokine secretion, cytolytic activity, perforin and/or granzyme activity and the like.
  • a signaling or co-stimulatory domain can include all or a portion of, but is not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, and/or B7-H3, and/or a ligand that specifically binds with CD83.
  • LFA-1 lymphocyte function-associated antigen-1
  • the vector encoding the chimeric antigen receptor further comprises a sequence for a co-stimulatory domain, wherein the co-stimulatory domain is an intracellular signaling domain that interacts with other intracellular mediators to mediate a cell response including an immune response, activation, proliferation, differentiation, cytokine secretion, cytolytic activity, perforin and/or granzyme activity and the like.
  • the vector comprises a sequence encoding a signaling domain.
  • the signaling domain comprises a 4-1BB domain and/or CD3-zeta domain.
  • the 4-1BB domain comprises the sequence set forth in SEQ ID NO: 6 (SEQ ID NO: 6; KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL).
  • the CD3-zeta domain comprises the sequence set forth in SEQ ID NO: 7 (SEQ ID NO: 7; RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQAL PPR).
  • a “chimeric antigen receptor” (CAR) described herein also known as chimeric T-cell receptor, refers to an artificial T-cell receptor or a genetically engineered receptor, which grafts a desired specificity onto an immune effector cell. These receptors can be used to graft the specificity of a monoclonal antibody or a binding portion thereof onto a T-cell, for example; with transfer of the coding sequence for the CAR to a recipient cell being facilitated by a retroviral vector.
  • the structure of the CAR can comprise single-chain variable fragments (scFv) derived from monoclonal antibodies, fused to CD3-zeta transmembrane and endodomain. Such molecules result in the transmission of a zeta signal in response to recognition by the scFv of its target.
  • a method of making genetically modified T-cells, which have a chimeric antigen receptor comprises separating, isolating, or enriching a CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells, from a mixed population of T-cells, so as to generate an isolated, separated, or enriched population of T-cells, stimulating the isolated, separated, or enriched population of T-cells so as to generate a stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells, transducing the stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells with a vector, wherein the vector encodes a chimeric antigen receptor and
  • T-cell receptors can be used as a therapy for cancer or a viral infection using a technique called “adoptive cell transfer.”
  • T-cells are removed from a patient and modified so that they express receptors specific for a molecule displayed on a cancer cell or a virus, or a virus-infected cell.
  • the genetically engineered T-cells which can then recognize and kill the cancer cells or the virus infected cells or promote clearance of the virus, are reintroduced into the patient.
  • a method of treating, inhibiting, or ameliorating a disease in a subject in need thereof is provided.
  • the method can comprise administering to the at least one composition or product combination, wherein the at least one composition or product combination comprises a population of genetically modified T-cells, wherein the population of genetically modified T-cells comprises a plurality of affinity selected CD8+ and/or CD4+ expressing T-cells, in the absence of, enriched from, substantially separated from or substantially isolated from CD8 ⁇ and/or CD4 ⁇ expressing T-cells, wherein said plurality of affinity selected CD8+ and/or CD4+ expressing T-cells have stimulated CD2, CD3, CD4 and/or CD28 receptors, wherein said plurality of affinity selected CD8+ and/or CD4+ expressing T-cells further comprise a gene encoding a chimeric antigen receptor and a cell surface selectable marker and, wherein said plurality of affinity selected CD8+ and/or CD4+ expressing T-cells have been re-stimulated with at least one cytokine, such as for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
  • an “antibody” as described herein refers to a large Y-shape protein produced by plasma cells that is used by the immune system to identify and neutralize foreign objects such as bacteria and viruses.
  • the antibody protein can comprise four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds. Each chain is composed of structural domains called immunoglobulin domains. These domains can contain 70-110 amino acids and are classified into different categories according to their size and function.
  • the ligand binding domain is an antibody fragment, desirably, a binding portion thereof.
  • the antibody fragment or binding portion thereof present on a CAR is specific for CD19.
  • a “single chain variable fragment” or scFv is a fusion protein that comprises the variable regions of the heavy chain (VH) and the light chains (VL) of an immunoglobulin that is connected with a short linker peptide.
  • the linker can comprise glycine for flexibility and hydrophilic amino acids, for example serine or threonine for solubility.
  • the linker can connect the N-terminus of the VH with the C-terminus of the VL or it can connect the C-terminus of the VH with the N-terminus of the VL.
  • the ligand binding domain present on a CAR is a single chain variable fragment (scFv).
  • the scFv domain present on a CAR is specific for a CD19 present on a tumor cell.
  • “FMC63” is a CD19 specific monoclonal antibody.
  • CD19 is a protein that is found on the surface of white blood cells and can assemble with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
  • CD19 is expressed on follicular dendritic cells and B cells.
  • CD19 is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells.
  • CD19 primarily acts as a B cell co-receptor in conjunction with CD21 and CD81.
  • the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase.
  • T-cells several surface molecules form the antigen receptor and form a complex on B lymphocytes.
  • CD19 is associated with severe immunodeficiency syndromes characterized by diminished antibody production.
  • aberrant expression of CD19 is a marker of monocytic lineage in acute myelogenous leukemia.
  • CD19 is a hallmark of B-cells, the protein can be used to diagnose cancers that arise from this type of cell, notably B-cell lymphomas. Since 2011, treatments targeting CD19 have begun to enter trials.
  • Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers.
  • the protein plays an active role in driving the growth of these cancers, by stabilizing the concentrations of the MYC oncoprotein.
  • CD19 and its downstream signaling can be attractive therapeutic targets.
  • a method of making genetically modified T-cells, which have a chimeric antigen receptor comprises separating, enriching, isolating, or purifying a population of CD8+ expressing T-cells and/or a population of CD4+ expressing T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells, from a mixed population of T-cells, from a mixed population of T-cells so as to generate an isolated, separated, enriched, or purified population of T-cells, stimulating the isolated, separated, enriched, or purified population of T-cells so as to generate a stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells, transducing the stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells with
  • the vector further comprises a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the vector further comprises a sequence encoding a spacer.
  • the ligand binding domain of the chimeric antigen receptor comprises an antibody, or a binding portion thereof.
  • the ligand binding domain of the chimeric antigen receptor comprises a single chain variable fragment (scFv), or a binding portion thereof.
  • the ligand binding domain of the chimeric antigen receptor comprises FMC63, or a binding portion thereof.
  • the ligand binding domain of the chimeric antigen receptor is specific for CD19.
  • “Purification” of T-cells as described herein refers to the isolation of highly purified, functional T-cells for research or for methods for generating T-cells for therapy.
  • “Isolation” of T-cells, or “separating” of T-cells, as described herein refers to a procedure of isolating or separating the desired T-cells, T-cell populations, or subpopulations from contaminating cell populations or other components, for example by using techniques, such as indirect panning.
  • cells can be isolated, separated, or selected by their capacity to bind to an antibody that is attached to a support, such as a plastic or poly carbonate surface, bead, particle, plate, or well. Cells can bind on the basis of particular cell surface markers.
  • the desired T-cell populations are “enriched” meaning that the population of the desired T-cells is greater after enrichment than that of the native population from which the T-cells originated.
  • the CD8+ expressing population of T-cells and/or CD4+ expressing population of T-cells are isolated, enriched, purified or separated from undesired components using CD8 specific antibodies and/or CD4 specific antibodies.
  • the CD8+ expressing population of T-cells and/or CD4+ expressing population of T-cells are isolated, enriched, or purified using flow cytometry.
  • the CD8+ expressing population of T-cells and/or CD4+ expressing population of T-cells are isolated, enriched, purified, or separated using immunomagnetic selection.
  • the CD8+ expressing population of T-cells and/or CD4+ expressing population of T-cells are isolated, enriched, purified, or separated using antibodies against CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28, CD8, CD4, and/or CD62L.
  • the CD8+ expressing population of T-cells and/or CD4+ expressing population of T-cells are isolated, enriched, purified, or separated by using antibodies against CD27, CD28 and/or CD62L.
  • the method is performed with isolated, enriched, or separated CD4+ expressing T-cells in the absence of or in greater abundance than the amount of CD8+ expressing cells in the mixed population of T-cells used for the isolation, enrichment, or purification. In some alternatives, the method is performed with isolated, enriched, or separated CD8+ in the absence of or in greater abundance than the amount of CD4+ expressing cells in the mixed population of T-cells used for the isolation, enrichment, or purification.
  • “Stimulation” or activation of T-cells refers to the method of inducing a T-cell to initiate a response, such as a signal transduction response, e.g., proliferation, while preserving T-cell viability and immune function.
  • a signal transduction response e.g., proliferation
  • simultaneous signaling to TCR/CD3 and CD8 can trigger a physiological activation and expansion of human T-cells.
  • T-cells may proliferate extensively in vitro.
  • a method of making genetically modified T-cells, which have a chimeric antigen receptor comprises isolating, separating, enriching, or purifying a CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells, so as to generate an isolated, separated, purified, or enriched population of T-cells, stimulating the isolated, separated, purified, or enriched population of T-cells so as to generate a stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells, transducing the stimulated population of CD8+ expressing T-cells and/or CD4+ expressing T-cells with a vector, wherein the vector encodes a chimeric antigen receptor and a marker sequence
  • the stimulating is performed with an antibody-bound support, such as a bead or particle. In some alternatives, the stimulating is performed with an antibody-bound support comprising anti-TCR, anti-CD2, anti-CD3, anti-CD4 and/or anti-CD28 antibodies. In some alternatives, the stimulating is performed with an antibody-bound support comprising anti-CD3 and/or anti-CD28 antibodies. In some alternatives, the method further comprises removing the antibody-bound support, such as beads or particles.
  • T-cells or “T lymphocytes” as used herein can be from any mammal, preferably a primate, including monkeys or humans, a companion animal such as a dog, cat, or horse, or a domestic animal, such as a sheep, goat, or cattle.
  • the T-cells are allogeneic (from the same species but different donor) as the recipient subject; in some alternatives the T-cells are autologous (the donor and the recipient are the same); in some alternatives the T-cells arc syngeneic (the donor and the recipients are different but are identical twins).
  • CD8+ expressing T-cell or “CD8+ T-cell,” used synonymously throughout, is also known as a TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T-cell or killer T-cell.
  • CD8+ T-cells are T-lymphocytes that can kill cancer cells, virally infected cells, or damaged cells.
  • CD8+ T-cells express T-cell receptors (TCRs) that can recognize a specific antigen.
  • CD8+ T-cells express CD8 on the surface.
  • CD8+ expressing T-cells have the ability to make some cytokines, however the amounts of cytokines made by CD8+ T-cells are not at a concentration that promotes, improves, contributes to, or induces engraftment fitness.
  • CD4+ expressing T-cell or “CD4+ T-cell,” used synonymously throughout, is also known as T helper cells, which play an important role in the immune system, and in the adaptive immune system.
  • CD4+ T-cells also help the activity of other immune cells by releasing T-cell cytokines. These cells help, suppress or regulate immune responses. They are essential in B cell antibody class switching, in the activation and growth of cytotoxic T-cells, and in maximizing bactericidal activity of phagocytes, such as macrophages.
  • CD4+ expressing T-cells have the ability to make some cytokines, however the amounts of cytokines made by CD4+ T-cells are not at a concentration that promotes, improves, contributes to, or induces engraftment fitness.
  • CD4+ T-cells are generally treated as having a pre-defined role as helper T-cells within the immune system. For example, when an antigen-presenting cell expresses an antigen on MHC class II, a CD4+ cell will aid those cells through a combination of cell to cell interactions (e.g. CD40 and CD40L) and through cytokines Nevertheless, there are rare exceptions; for example, sub-groups of regulatory T-cells, natural killer cells, and cytotoxic T-cells express CD4. All of the latter CD4+ expressing T-cell groups are not considered T helper cells.
  • Central memory T-cell refers to an antigen experienced CTL that expresses CD62L or CCR-7 and CD45RO on the surface thereof, and does not express or has decreased expression of CD45RA as compared to na ⁇ ve cells.
  • central memory cells are positive for expression of CD62L, CCR7, CD28, CD127, CD45RO, and/or CD95, and have decreased expression of CD54RA as compared to na ⁇ ve cells.
  • Effective memory T-cell refers to an antigen experienced T-cell that does not express or has decreased expression of CD62L on the surface thereof as compared to central memory cells, and does not express or has decreased expression of CD45RA as compared to na ⁇ ve cell.
  • effector memory cells are negative for expression of CD62L and/or CCR7, as compared to na ⁇ ve cells or central memory cells, and have variable expression of CD28 and/or CD45RA.
  • na ⁇ ve T-cells refers to a non-antigen experienced T lymphocyte that expresses CD62L and/or CD45RA, and/or does not express CD45RO ⁇ as compared to central or effector memory cells.
  • na ⁇ ve CD8+ T lymphocytes are characterized by the expression of phenotypic markers of na ⁇ ve T-cells including CD62L, CCR7, CD28, CD127, and/or CD45RA.
  • T E T-cells refers to a antigen experienced cytotoxic T lymphocyte cells that do not express or have decreased expression of CD62L, CCR7, CD28, and are positive for granzyme B and/or perforin, as compared to central memory or na ⁇ ve T-cells.
  • Engraftment fitness refers to the ability of a cell to grow and proliferate after the cells have entered the body, e.g., blood stream, through adoptive transfer. Engraftment can usually occur within two to four weeks after the transfer. Engraftment can be monitored by checking blood counts for a specific cell on a frequent basis.
  • the method can comprise administering a composition or product combination comprising the genetically modified T-cells, as described herein.
  • the method can further comprise monitoring the subject by checking the blood counts for the genetically modified T-cells that expresses a chimeric antigen receptor e.g., by identifying the presence or absence of a marker associated with the transferred T-cells.
  • T-cells with improved engraftment fitness may have specific markers on the cell surface that confer generation and long term maintenance of T-cell immunity.
  • CD28 is a protein expressed on T-cells that provide co-stimulatory signals required for T-cell activation and survival.
  • CD27 is required for generation and long-term maintenance of T-cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis.
  • L-selectin, also known as CD62L is a cell adhesion molecule found on lymphocytes.
  • L-selectin functions as a “homing receptor” for lymphocytes or T-cells to enter secondary lymphoid tissues via high endothelial venues.
  • Ligands present on endothelial cells will bind to lymphocytes expressing L-selectin, slowing lymphocyte trafficking through the blood, and can facilitate entry into a secondary lymphoid organ at that point.
  • the T-cells comprise at least one receptor that promotes, induces, improves, or contributes to engraftment fitness.
  • the at least one receptor is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L. In some alternatives, the at least one receptor is CD27, CD28 and/or CD62L.
  • methods are described in which CD4+ and CD8+ expressing T-cells are genetically modified by transduction of genetic material in the form of a vector such that the genetically modified CD4+ and CD8+ expressing T-cells expresses a specific chimeric antigen receptor. In some alternatives of the genetically modified CD4+ and CD8+ T-cells, the genetically modified CD4+ and CD8+ T-cells are further modified to improve or enhance engraftment fitness.
  • Cytokines refers to small proteins (5-25 kDa) that are important in cell signaling. Cytokines are released by cells and affect the behavior of other cells, and sometimes the releasing cell itself, such as a T-cell. Cytokines can include, for example, chemokines, interferons, interleukins, lymphokines, and tumor necrosis factor. Cytokines can be produced by a broad range of cells, which can include, for example, immune cells like macrophages, B lymphocytes, T lymphocytes and mast cells, as well as, endothelial cells, fibroblasts, and various stromal cells.
  • Cytokines can act through receptors, and are important in the immune system as the cytokines can modulate the balance between humoral and cell-based immune responses, and they can regulate the maturation, growth, and responsiveness of particular cell populations. Some cytokines enhance or inhibit the action of other cytokines in complex ways.
  • cytokines can include, for example, Acylation stimulating protein, Adipokine, Albinterferon, CCL1, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL5, CCL6, CCL7, CCL8, CCL9, Chemokine, Colony-stimulating factor, CX3CL1, CX3CR1, CXCL1, CXCL10, CXCL11, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL9, Erythropoietin, Gc-MAF, Granulocyte colony-stimulating factor, Granulocyte macrophage colony-stimulating factor,
  • a transduced population of CD8+ expressing T-cells and/or CD4+ expressing T-cells is contacted with at least one cytokine so as to generate a transduced, cytokine-stimulated population of CD8+ T-cells and/or CD4+ T-cells.
  • the at least one cytokine utilized comprises GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-2, and/or IL-21.
  • the period of contact with the cytokine is at least one day, such as for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or any time that is within a range of times defined by any two of the aforementioned time points.
  • Interleukins are cytokines that the immune system depends largely upon.
  • Examples of interleukins include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, 11-7, IL-8/CXCL8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and/or IL-36.
  • IL-1 for example can function in the maturation & proliferation of T-cells.
  • IL-2 for example, can stimulate growth and differentiation of T-cell response.
  • IL-3 for example, can promote differentiation and proliferation of myeloid progenitor cells.
  • IL-4 for example, can promote proliferation and differentiation.
  • IL-7 for example, can promote differentiation and proliferation of lymphoid progenitor cells, involved in B, T, and NK cell survival, development, and homeostasis.
  • IL-15 for example, can induce production of natural killer cells.
  • IL-21 for example, co-stimulates activation and proliferation of CD8+ T-cells, augments NK cytotoxicity, augments CD40-driven B cell proliferation, differentiation and isotype switching, and promotes differentiation of Th17 cells.
  • a method of making a genetically modified T-cell comprises purifying, separating, enriching, or isolating a CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells, so as to generate an isolated, separated, enriched, or purified population of T-cells, stimulating the isolated, separated, enriched, or purified population of T-cells so as to generate a stimulated population of CD8+ T-cells and/or CD4+ T-cells, transducing the stimulated population of CD8+ T-cells and/or CD4+ T-cells with a vector, wherein the vector encodes a chimeric antigen receptor and a marker sequence, wherein said marker sequence encodes a cell
  • the at least one cytokine comprises GM-CSF, IL-7, IL-12, IL-18, IL-15, IL-2, and/or IL-21. In some alternatives, the at least one cytokine comprises IL/7, IL-15 and/or IL-21. In some alternatives, the at least one cytokine comprises IL-2, IL-15 and/or IL-21. In some alternatives of the method, the cytokine contacting is performed for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or a period of time within a range defined by any two of these time periods. In some alternatives, the addition of the at least one cytokine improves, enhances, promotes, or induces engraftment fitness.
  • the enriched CD4+ expressing T-cells are contacted, for example propagated, in 5 ng/mL recombinant human IL-7 (rhIL-7) and/or 0.5 ng/mL recombinant human IL-15 (rhIL-15).
  • the enriched CD8+ expressing T-cells are contacted, for example propagated, in 50 U/mL recombinant human IL-2 (rhIL-2) and/or 0.5 ng/mL recombinant human IL-15 (rhIL-15).
  • the enriched CD4+ expressing T-cells are contacted, for example propagated, in 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, 0.4 ng/mL, 0.5 ng/mL, 0.6 ng/mL, 0.7 ng/mL, 0.8 ng/mL, 0.9 ng/mL, or 1.0 ng/mL rhIL-7 or in an amount that is within a range defined by any two of the aforementioned amounts of rhIL-7 and/or 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, 0.4 ng/mL, 0.5 ng/mL, 0.6 ng/mL, 0.7 ng/mL, 0.8 ng/mL, 0.9 ng/mL, or 1.0 ng/mL rhIL-15 or in an amount that is within a range defined by any two of the aforementioned amounts of rhIL-15.
  • the enriched CD8+ expressing T-cells are contacted, for example propagated, in 10 U/mL, 20 U/mL, 30 U/mL, 40 U/mL, 50 U/mL, 60 U/mL, 70 U/mL, 80 U/mL, 90 U/mL, or 100 U/mL of rhIL-2 or in an amount that is within a range defined by any two of the aforementioned amounts of rhIL-2 and/or 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, 0.4 ng/mL, 0.5 ng/mL, 0.6 ng/mL, 0.7 ng/mL, 0.8 ng/mL, 0.9 ng/mL, or 1.0 ng/mL rhIL-7 and/or 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, 0.4 ng/mL, 0.5 ng/mL, 0.6 ng/mL,
  • the aforementioned cytokines and amounts are co-administered to the T-cells, e.g., in a mixture or added shortly after one another, and in other alternatives, the aforementioned cytokines are contacted with the T cells separately, e.g., separated by a time period of 1-10 minutes or 1-10 hours.
  • Enriched and “depleted” are also used herein to describe amounts of cell types in a mixture refers to the subjecting of the mixture of the cells to a process or step, which results in an increase in the number of the “enriched” type and a decrease in the number of the “depleted” cells.
  • a mixture or composition can contain 60, 70, 80, 90, 95, or 99 percent or more, or any value within a range defined by any two of these values (in number or count) of the “enriched” cells and 40, 30, 20, 10, 5 or 1 percent or less or any value within a range defined by any two of these values (in number or count) of the “depleted” cells.
  • enriching the transduced, cytokine-stimulated population of CD8+ T-cells and/or CD4+ T-cells by affinity selection of a cell surface marker is contemplated, such that an enriched population of transduced, cytokine-stimulated CD8+ T-cells and/or CD4+ T-cells is generated.
  • “Propagating cells” or propagation refers to steps to allow proliferation, expansion, growth and reproduction of cells.
  • cultures of CD8+ T-cells and CD4+ T-cells can typically be incubated under conditions that are suitable for the growth and proliferation of T lymphocytes.
  • the CD4+ expressing T-cells are propagated for at least 1 day and may be propagated for 20 days, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or for a period that is within a range defined by any two of the aforementioned time periods.
  • the CD8+ expressing T-cells are propagated for at least 1 day and may be propagated for 20 days, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or for a period that is within a range defined by any two of the aforementioned time periods.
  • Affinity selection refers to the selection of a specific molecule or cell having a selectable cell surface marker by binding to the molecule or marker or an epitope present thereon with a binding affinity agent, which allows for one to select out the specific molecule or cell of interest. Affinity selection can be performed by, for example, antibodies, conjugated antibodies, lectins, aptamers, and/or peptides. In some alternatives, of the method of making genetically modified T-cells, the separating of the CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells is performed by affinity selection for T-cells having an epitope present on CD8 and/or CD4.
  • anti-CD8 or anti-CD4 antibodies or binding portions thereof are used to select out the cells of interest.
  • the separating of the CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells is performed by flow cytometry.
  • the separating of the CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells is performed by immuno-magnetic selection.
  • the anti-CD8 or the anti-CD4 antibodies are conjugated to a solid support such as, for example, an inert bead or an inert particle.
  • T cell precursors refers to lymphoid precursor cells that can migrate to the thymus and become T cell precursors, which do not express a T cell receptor. All T cells originate from hematopoietic stem cells in the bone marrow. Hematopoietic progenitors (lymphoid progenitor cells) from hematopoietic stem cells populate the thymus and expand by cell division to generate a large population of immature thymocytes. The earliest thymocytes express neither CD4 nor CD8, and are therefore classed as double-negative (CD4 CD8) cells.
  • CD4 CD8 double-negative
  • thymocytes As they progress through their development, they become double-positive thymocytes (CD4 + CD8 + ), and finally mature to single positive (CD4 + CD8 ⁇ or CD4 + CD8 + ) thymocytes that are then released from the thymus to peripheral tissues. About 98% of thymocytes die during the development processes in the thymus by failing either positive selection or negative selection, whereas the other 2% survive and leave the thymus to become mature immunocompetent T cells.
  • the double negative (DN) stage of the precursor T cell is focused on producing a functional ⁇ -chain whereas the double positive (DP) stage is focused on producing a functional ⁇ -chain, ultimately producing a functional ⁇ T cell receptor.
  • the T cell expresses an invariant ⁇ -chain but rearranges the ⁇ -chain locus. If the rearranged ⁇ -chain successfully pairs with the invariant ⁇ -chain, signals are produced which cease rearrangement of the ⁇ -chain (and silence the alternate allele) and result in proliferation of the cell. Although these signals require this pre-TCR at the cell surface, they are dependent on ligand binding to the pre-TCR.
  • thymocytes will then express both CD4 and CD8 and progresses to the double positive (DP) stage where selection of the ⁇ -chain takes place. If a rearranged ⁇ -chain does not lead to any signaling (e.g. as a result of an inability to pair with the invariant ⁇ -chain), the cell may die by neglect (lack of signaling).
  • Hematopoietic stem cells are precursor cells that can give rise to myeloid cells such as, for example, macrophages, monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells and lymphoid lineages (such as, for example, T-cells, B-cells, NK-cells).
  • HSCs have a heterogeneous population in which three classes of stem cells exist, which are distinguished by their ratio of lymphoid to myeloid progeny in the blood (L/M).
  • cryopreservation is a process of preserving cells, whole tissues, or substances susceptible to damage by cooling to sub-zero temperatures. At the low temperatures any enzymatic or chemical activity, which can cause damage to the cells, tissue or substances in question are effectively stopped. Cryopreservation methods seek to reach low temperatures without causing additional damage caused by the formation of ice during freezing. Traditional cryopreservation has relied on coating the material to be frozen with a class of molecules termed cryoprotectants. New methods are constantly being investigated due to the inherent toxicity of many cryoprotectants. Cryopreservation methods are known to those skilled in the art. In some alternatives of the method of making genetically modified T-cells, which have a chimeric antigen receptor, the method can further comprise cryopreserving the genetically modified T-cells.
  • a population of genetically modified T-cells comprises a plurality of affinity selected CD8+ and/or CD4+ expressing T-cells, in the absence of, enriched over, or isolated from CD8 ⁇ and/or CD4 ⁇ T-cells, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells have stimulated CD2, CD3, CD4 and/or CD28 receptors, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise a gene encoding a chimeric antigen receptor and a cell surface selectable marker and, wherein said plurality of affinity selected CD8+ and/or CD4+ expressing T-cells have been re-stimulated with at least one cytokine, such as for at least 1, 2, 3,
  • the selected CD8+ and/or CD4+ T-cells are generated by methods provided herein.
  • the at least one cytokine comprises GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-2, and/or IL-21.
  • the at least one cytokine comprises IL/7, IL-15 and/or IL-21.
  • the at least one cytokine comprises IL-2, IL-15 and/or IL-21.
  • the plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise at least one receptor that promotes, induces, enhances or contribute to engraftment fitness.
  • the at least one receptor that promotes, enhances, induces, or contributes to engraftment fitness is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L. In some alternatives, the at least one receptor that promotes, enhances, contributes to, or induces engraftment fitness is CD27, CD28 and/or CD62L.
  • the plurality of affinity selected CD8+ and/or CD4+ expressing T-cells further comprises a vector having a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker.
  • the vector further comprises a sequence encoding a spacer.
  • the spacer comprises an IgG4 hinge.
  • the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector. In some alternatives, the viral vector is a lentivirus vector. In some alternatives, the cell surface selectable marker codes for a truncated epidermal growth factor receptor (EGFRt).
  • the ligand binding domain comprises an antibody, or a binding portion thereof. In some alternatives, the ligand binding domain comprises a single chain variable fragment (scFv), or a binding portion thereof. In some alternatives, the ligand binding domain comprises FMC63, or a binding portion thereof. In some alternatives, the ligand binding domain is specific for CD19.
  • the population comprises isolated or enriched CD8+ expressing T-cells in the absence of, enriched over, substantially depleted of CD4+ T-cells. In some alternatives, the population comprises isolated or enriched CD4+ T-cells in the absence of, enriched over, or substantially depleted of CD8+ T-cells.
  • the adoptive cellular immunotherapy compositions are useful in the treatment of a disease or cancer.
  • a composition or product combination for human therapy is provided, wherein the composition or product combination comprises a pharmaceutical excipient and at least one population of genetically modified T-cells according to any one or more of the alternative T-cells or population of genetically modified T-cells prepared or obtained as described herein.
  • the composition or product combination comprises a population of genetically modified T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, wherein the population comprises isolated CD8+ T-cells in the absence of enriched over, substantially depleted of CD4+ T-cells.
  • the composition or product combination comprises a population of genetically modified T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, wherein the population comprises isolated CD4+ T-cells in the absence of, enriched over, or substantially depleted of CD8+ T-cells.
  • the composition or product combination comprises a combination of isolated CD8+ T-cells in the absence of, enriched over, or substantially depleted of CD4+ T-cells and isolated CD4+ T-cells absence of, enriched over, or substantially depleted of CD8+ T-cells in a 1:1 ratio.
  • the population of genetically modified T-cells are mixed and administered or co-administered as separate formulations to a subject in need thereof in a CD4+ T-cell to CD8+ T-cell ratio that is 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or a ratio within a range defined by any two of these ratios.
  • the population of genetically modified T-cells are mixed and administered or co-administered as separate formulations to a subject in need thereof in a CD8+ T-cell to CD4+ T-cell ratio that is 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or a ratio within a range defined by any two of these ratios.
  • “Pharmaceutical excipient,” or pharmaceutical vehicle as described herein can refer to a carrier or inert medium used as a solvent in which the medicinally active agent or T-cells for treatment is formulated and or administered.
  • Vehicles can include polymeric micelles, liposomes, lipoprotein-based carriers, nano-particle carriers, dendrimers, and/or other vehicles for T-cells that are known to one skilled in the art.
  • An ideal vehicle or excipient can be non-toxic, biocompatible, non-immunogenic, biodegradable, and can avoid recognition by the host's defense mechanisms.
  • composition or product combination for human therapy wherein the composition or product combination comprises a pharmaceutical excipient and at least one population of genetically modified T-cells of any of the alternatives described herein.
  • the excipients are pharmaceutical vehicles.
  • the pharmaceutical vehicles include pharmaceutical compositions.
  • Acute lymphoblastic leukemia or acute lymphoid leukemia is a cancer of the white blood cells, characterized by the overproduction of cancerous, immature white blood cells, also known as lymphoblasts.
  • lymphoblasts are overproduced in the bone marrow and continuously multiply, causing damage and death by inhibiting the production of normal cells, such as, for example, red and white blood cells and platelets, in the bone marrow and by spreading to other organs.
  • ALL is most common in childhood with a peak incidence at 2-5 years of age, and another peak at an older age.
  • ALL are indicative of a reduced production of functional blood cells, because the leukemia wastes the resources of the bone marrow, which are normally used to produce new, functioning blood cells.
  • Symptoms can include fever, increased risk of infection, increased tendency to bleed, anemia, tachycardia, fatigue and headache. Between 50 to 70% of children and 40-50% of adults who achieve complete remission after initial therapy but then suffer a relapse can be able to go into a second complete remission.
  • Treatment for relapse after a first remission can be standard chemotherapy or experimental drugs, or more aggressive treatments such as stem cell transplants.
  • Treatment for relapse after a first remission can be standard chemotherapy or experimental drugs, or more aggressive treatments such as stem cell transplants.
  • HSCT allogeneic hematopoietic stem cell transplantation
  • a method of treating, inhibiting, or ameliorating a disease, such as a cancer, such as ALL, in a subject in need thereof comprises administering to the subject at least one composition or product combination of any one or more of the alternatives described herein, wherein the composition or product combination comprises genetically modified T-cells, which have a chimeric antigen receptor, wherein the T-cells are transduced, cytokine-stimulated CD8+ T-cells and/or CD4+ T-cells.
  • the method comprises administering a composition or product combination, wherein the composition or product combination comprises a population of genetically modified T-cells comprising isolated CD8+ T-cells absence of, enriched over, or substantially depleted of CD4+ T-cells. In some alternatives of the method, the method comprises administering a composition or product combination, wherein the composition or product combination comprises a population of genetically modified T-cells comprising isolated CD4+ T-cells absence of, enriched over, or substantially depleted of CD8+ T-cells.
  • the method further comprises administering a composition or product combination, wherein the composition or product combination comprises a population of genetically modified T-cells comprising isolated CD4+ T-cells absence of, enriched over, or substantially depleted of CD8+ T-cells. In some alternatives of the method, the method further comprises administering a composition or product combination, wherein the composition or product combination comprises a population of genetically modified T-cells comprising isolated CD8+ T-cells absence of, enriched over, or substantially depleted of CD4+ T-cells.
  • the method further comprises administering the composition or product combination, wherein the composition or product combination comprises isolated CD8+ T-cells absence of, enriched over, or substantially depleted of CD4+ T-cells and isolated CD4+ T-cells absence of, enriched over, or substantially depleted of CD8+ T-cells in a 1:1 ratio.
  • the population of genetically modified T-cells are mixed and administered or co-administered as separate formulations to a subject in need thereof in a CD4+ T-cell to CD8+ T-cell ratio that is 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or a ratio within a range defined by any two of these ratios.
  • the population of genetically modified T-cells are mixed and administered or co-administered as separate formulations to a subject in need thereof in a CD8+ T-cell to CD4+ T-cell ratio that is 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or a ratio within a range defined by any two of these ratios.
  • the subject is identified or selected to receive an anti-cancer therapy.
  • the method further comprises measuring or evaluating an inhibition of a disease.
  • the method further comprises providing said subject an additional anti-cancer therapy before, during, or after administration of the composition or product combination of any one or more of the alternatives described herein.
  • composition or product combination of any one or more of the alternatives described herein are administered to said subject by adoptive cell transfer. In some alternatives, the composition or product combination of any one or more of the alternatives described herein, are administered to said subject after said subject has received another form of anti-cancer therapy. In some alternatives, the composition or product combination of any one or more of the alternatives described herein, are administered to said subject after said subject has received another form of anti-cancer therapy. In some alternatives, the subject is suffering from leukemia. In some alternatives, the subject has recurrent and/or refractory CD19+ childhood acute lymphoblastic leukemia (ALL).
  • ALL acute lymphoblastic leukemia
  • the subject has recurrent and/or chemotherapy refractory CD19+ acute lymphoblastic leukemia (ALL).
  • ALL acute lymphoblastic leukemia
  • the subject is suffering from an autoimmune disease.
  • the subject is suffering from a post-HSCT relapse.
  • compositions described herein provide for CD4+ and/or CD8+ expressing T lymphocytes, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells.
  • T lymphocytes can be collected in accordance with known techniques and enriched or depleted by known techniques, such as affinity binding to antibodies such as flow cytometry and/or immunomagnetic selection. After enrichment and/or depletion steps, in vitro expansion of the desired T lymphocytes can be carried out in accordance with known techniques (including but not limited to those described in U.S. Pat. No. 6,040,177 to Riddell et al., hereby expressly incorporated by reference in its entirety).
  • the T-cells are autologous T-cells i.e., obtained from the patient to which the cells are delivered.
  • the T cells are precursor T cells.
  • the precursor T cells are a hematopoietic stem cells (HSC).
  • the desired T-cell population or subpopulation can be expanded by adding an initial T lymphocyte population to a culture medium in vitro, and then adding to the culture medium feeder cells, such as non-dividing peripheral blood mononuclear cells (PBMC), (e.g., such that the resulting population of cells contains at least 5, 10, 20, or 40 or more PBMC feeder cells for each T lymphocyte in the initial population to be expanded); and incubating the culture (e.g. for a time sufficient to expand the numbers of T-cells).
  • the non-dividing feeder cells can comprise gamma-irradiated PBMC feeder cells.
  • the PBMC are irradiated with gamma rays at 3000, 3200, 3300, 3400, 3500, or 3600 rads to prevent cell division, or within a range of rads defined by any two of the aforementioned rads.
  • the order of addition of the T-cells and feeder cells to the culture media can be reversed if desired.
  • the culture can be incubated under conditions that are suitable for the growth of T lymphocytes.
  • the temperature will generally be at least 25 degrees Celsius, preferably at least 30 degrees, more preferably 37 degrees, or any other temperature within a range defined by any two of these temperatures.
  • the T lymphocytes expanded include CD8+ cytotoxic T lymphocytes (CTL) and CD4+ helper T lymphocytes that can be specific for an antigen present on a human tumor or a pathogen and express a chimeric antigen receptor.
  • CTL cytotoxic T lymphocytes
  • CD4+ helper T lymphocytes that can be specific for an antigen present on a human tumor or a pathogen and express a chimeric antigen receptor.
  • the expansion method or propagation can further comprise adding non-dividing EBV-transformed lymphoblastoid cells (LCL) as feeder cells.
  • LCL can be irradiated with gamma rays in the range of 6000, 7000, 8000, 9000, or 10,000 rads, or within a range of rads defined by any two of the aforementioned rads.
  • the LCL feeder cells can be provided in any suitable amount, such as a ratio of LCL feeder cells to initial T lymphocytes of at least 10:1.
  • the expansion method or propagation can further comprise adding anti-CD3 and/or anti CD28 antibody to the culture medium (e.g., at a concentration of at least 0.5 ng/ml).
  • the method of making genetically modified T-cells, which have a chimeric antigen receptor method can further comprise adding IL-2, IL-15, and/or IL-21 to the culture medium (e.g., wherein the concentration of IL-2 is at least 10 units/ml).
  • the method of making genetically modified T-cells, which have a chimeric antigen receptor method can further comprise adding IL-7, IL-15, and/or IL21 to the culture medium (e.g., wherein the concentration of IL-2 is at least 10 units/ml).
  • the culture medium e.g., wherein the concentration of IL-2 is at least 10 units/ml.
  • CD8+ cells can also be obtained by using standard methods.
  • CD8+ cells are further sorted into na ⁇ ve, central memory, and effector memory cells by identifying cell surface antigens that are associated with each of those types of CD8+ cells.
  • memory T-cells are present in both CD62L+ and CD62L ⁇ subsets of CD8+ peripheral blood lymphocytes.
  • PBMC are sorted into CD62L-CD8+ and CD62L+CD8+ fractions after staining with anti-CD8 and anti-CD62L antibodies.
  • the expression of phenotypic markers of central memory T CM include CD45RO, CD62L, CCR7, CD28, CD3, and/or CD127 and/or are negative or low for granzyme B and/or CD45RA.
  • central memory T-cells are CD28+, CD27+, CD45RO+, CD62L+, and/or CD8+ T-cells.
  • na ⁇ ve CD8+ T lymphocytes are characterized by the expression of phenotypic markers of na ⁇ ve T-cells including CD62L, CCR7, CD27, CD28, CD3, CD127, and/or CD45RA.
  • Whether a cell or cell population is positive for or expresses a particular cell surface marker can be determined by flow cytometry using a specific antibody that is specific for the surface marker and an isotype matched control antibody.
  • a cell population negative for a marker refers to the absence of significant binding of the cell population with the specific antibody above the isotype control, indicative of a lack of expression of said marker; positive refers to uniform binding of the cell population above the isotype control indicative of the expression of the marker.
  • a decrease in expression of one or markers refers to loss of 1 log 10 in the mean fluorescence intensity and/or decrease of percentage of cells that exhibit the marker of at least 20% of the cells, 25% of the cells, 30% of the cells, 35% of the cells, 40% of the cells, 45% of the cells, 50% of the cells, 55% of the cells, 60% of the cells, 65% of the cells, 70% of the cells, 75% of the cells, 80% of the cells, 85% of the cells, 90% of the cell, 95% of the cells, or 100% of the cells or any % within a range of % s defined by any two of these values when compared to a reference cell population.
  • a cell population positive for one or markers refers to a percentage of cells that exhibit the marker of at least 50% of the cells, 55% of the cells, 60% of the cells, 65% of the cells, 70% of the cells, 75% of the cells, 80% of the cells, 85% of the cells, 90% of the cell, 95% of the cells, or 100% of the cells or any % within a range of % s defined by any two of these values when compared to a reference cell population.
  • CD4+ T helper cells are sorted into na ⁇ ve, central memory, and effector cells by identifying cell populations that have cell surface antigens.
  • CD4+ lymphocytes can be obtained by standard methods.
  • na ⁇ ve CD4+ T lymphocytes are CD45RO ⁇ , CD45RA+, CD62L+, CD27+, CD28+, and/or CD4+ T-cells.
  • central memory CD4+ cells are CD62L+ and/or CD45RO+.
  • effector CD4+ cells are CD62L- and/or CD45RO ⁇ .
  • effector CD4+ cells are CD28+, CD27+ and/or CD62L+.
  • populations of CD4+ and CD8+ that are antigen specific can be obtained by stimulating na ⁇ ve or antigen specific T lymphocytes with antigen.
  • antigen-specific T-cell lines or clones can be generated to Cytomegalovirus antigens by isolating T-cells from infected subjects and stimulating the cells in vitro with the same antigen. Na ⁇ ve T-cells can also be used. Any number of antigens from tumor cells can be utilized as targets to elicit T-cell responses.
  • the adoptive cellular immunotherapy compositions are useful in the treatment of a disease or disorder including a solid tumor, hematologic malignancy, breast cancer or melanoma.
  • the introduced gene or genes can improve the efficacy of therapy by promoting the viability and/or function of transferred T-cells; or they can provide a genetic marker to permit selection and/or evaluation of in vivo survival or migration; or they can incorporate functions that improve the safety of immunotherapy, for example, by making the cell susceptible to negative selection in vivo as described by Lupton S. D. et al., Mol.
  • the T cells are precursor T cells.
  • the precursor T cells are a hematopoietic stem cells (HSC).
  • T-cells are modified with chimeric receptors, as described herein.
  • the T-cells are obtained from the subject to be treated, in other alternatives, the lymphocytes are obtained from allogeneic human donors, preferably healthy human donors.
  • the T cells are precursor T cells.
  • the precursor T cells are a hematopoietic stem cells (HSC).
  • chimeric receptors comprise a ligand binding domain that specifically binds to surface molecule on a cell, a polypeptide spacer region, a transmembrane domain and an intracellular signaling domain as described herein.
  • the ligand binding domain is a single-chain antibody fragment (scFv) that is derived from the variable heavy (VH) and variable light (VL) chains of a monoclonal antibody (mAb).
  • scFv single-chain antibody fragment
  • VH variable heavy
  • VL variable light chains of a monoclonal antibody
  • Co-stimulatory signals can also be provided through the chimeric receptor by fusing the co-stimulatory domain of CD28 and/or 4-1BB to the CD3 ⁇ chain.
  • Chimeric receptors are specific for cell surface molecules independent from HLA, thus overcoming the limitations of TCR-recognition including HLA-restriction and low levels of HLA-expression on tumor cells.
  • the same or a different chimeric receptor can be introduced into each of population of CD4+ and CD8+ T lymphocytes.
  • the chimeric receptor in each of these populations has a ligand binding domain that specifically binds to the same ligand on the cell.
  • the cellular signaling modules can differ.
  • the intracellular signaling domain of the CD8+ cytotoxic T-cells is the same as the intracellular signaling domain of the CD4+ helper T-cells.
  • the intracellular signaling domain of the CD8+ cytotoxic T-cells is different than the intracellular signaling domain of the CD4+ helper T-cells.
  • an anti-CD19 CAR is introduced into one population of lymphocytes and an EGFR specific CAR is introduced into another population of lymphocytes.
  • each of the CD4 or CD8 T lymphocytes are sorted in to na ⁇ ve, central memory, effector memory or effector cells prior to transduction, as described herein. In some alternatives, each of the CD4 or CD8 T lymphocytes are sorted into na ⁇ ve, central memory, effector memory, or effector cells after transduction.
  • the viral vectors which have been used in this way include virus vectors derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentiviral vectors, and retroviruses.
  • virus vectors derived from simian virus 40 include virus vectors derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentiviral vectors, and retroviruses.
  • AAV adeno-associated virus
  • retroviruses retroviruses
  • hematopoietic or lymphoid cells including calcium phosphate transfection, protoplast fusion, electroporation, and infection with recombinant adenovirus, adeno-associated virus and retrovirus vectors.
  • Primary T lymphocytes have been successfully transduced by electroporation and by retroviral or lentiviral infection.
  • Retroviral and lentiviral vectors provide a highly efficient method for gene transfer into eukaryotic cells. Moreover, retroviral or lentiviral integration takes place in a controlled fashion and results in the stable integration of one or a few copies of the new genetic information per cell.
  • the T-cells can include in the T-cells a positive marker that enables the selection of cells of the negative selectable phenotype in vitro.
  • the positive selectable marker can be a gene that upon being introduced into the host cell expresses a dominant phenotype permitting positive selection of cells carrying the gene.
  • Genes of this type are known in the art, and include, inter alia, hygromycin-B phosphotransferase gene (hph) which confers resistance to hygromycin B, the amino glycoside phosphotransferase gene (neo or aph) from Tn5 which codes for resistance to the antibiotic G418, the dihydrofolate reductase (DHFR) gene, the adenosine deaminase gene (ADA), and the multi-drug resistance (MDR) gene.
  • the positive marker is an EGFR truncated protein for cell selection.
  • transduction is carried out using lentiviral vectors.
  • CD4+ and CD8+ cells each can separately be modified with an expression vector encoding a chimeric receptor to form defined populations.
  • these cells are then further sorted into subpopulations of na ⁇ ve, central memory and effector cells as described above by sorting for cell surface antigens unique to each of those cell populations.
  • CD4+ and CD8+ cells that proliferate in response to antigen or tumor targets are selected.
  • CD4+ cells that proliferate vigorously when stimulated with antigen or tumor targets as compared to sham transduced cells, or CD8+ transduced cells are selected.
  • CD4+ and CD8+ cells are selected that are cytotoxic for antigen bearing cells.
  • CD4+ are expected to be weakly cytotoxic as compared to CD8+ cells.
  • transduced lymphocytes such as CD8+ central memory cells
  • transduced lymphocytes are selected that provide for cell killing in vivo using an animal model established for the particular type of cancer.
  • animal models are known to those of skill in the art and exclude human beings.
  • not all chimeric receptor constructs transduced into lymphocytes confer the ability to kill tumor cells in vivo despite the ability to become activated and kill cells in vitro.
  • combinations of CD4+ and CD8+ T-cells will be utilized in compositions.
  • combinations of chimeric receptor transduced CD4+ cells can be combined with chimeric receptor transduced CD8+ cells of the same ligand specificity or combined with CD8+ T-cells that are specific for a distinct tumor ligand.
  • chimeric receptor transduced CD8+ cells are combined with chimeric receptor transduced CD4+ cells specific for a different ligand expressed on the tumor.
  • chimeric receptor modified CD4+ and CD8+ cells are combined.
  • CD8+ and CD4+ cells can be combined in different ratios for example, a 1:1 ratio of CD8+ and CD4+, a ratio of 10:1 of CD8+ to CD4+, or a ratio of 100:1 of CD8+ to CD4+ or any other ratio within a range defined by any two of the aforementioned ratio values.
  • the combined population is tested for cell proliferation in vitro and/or in vivo, and the ratio of cells that provides for proliferation of cells is selected.
  • CD4+ and CD8+ cells can be further separated into subpopulations, such as na ⁇ ve, central memory, and effector memory cell populations.
  • na ⁇ ve CD4+ cells are CD45RO ⁇ , CD45RA+, CD62L+, CD28+, CD27+, and/or CD4+ positive T-cells.
  • central memory CD4+ cells are CD62L positive and/or CD45RO positive.
  • effector CD4+ cells are CD62L negative and/or CD45RO positive.
  • central memory CD4+ cells are CD62L+, CD28+ and/or CD27+.
  • the cell populations are preferably expanded in vitro until a sufficient number of cells are obtained to provide for at least one infusion into a human subject, typically around 10 4 cells/kg to 10 9 cells/kg.
  • the transduced cells are cultured in the presence of antigen bearing cells, anti CD3, anti CD28, IL 2, IL-7, IL 15, and/or IL-21 and/or combinations thereof.
  • the T-cells are stimulated in the presence of an antibody-bound support, such as a bead or particle.
  • the T-cells are stimulated with an antibody-bound support, wherein the antibody-bound support comprises anti-TCR, anti-CD2, anti-CD3, anti-CD4 and/or anti-CD28 antibodies. In some alternatives, the T-cells are stimulated with an antibody-bound support, wherein the antibody-bound support comprises anti-CD3 and/or anti-CD28 antibodies.
  • modified na ⁇ ve or central memory CD4+ cells are combined with modified central memory CD8+ T-cells to provide a synergistic cytotoxic effect on an antigen bearing cells, such as a B-cell comprising CD19 on the cell surface.
  • the disclosure provides for an adoptive cellular immunotherapy composition comprising a genetically modified T lymphocyte cell preparation as described herein.
  • the T lymphocyte cell preparation comprises CD4+ T-cells that have a chimeric receptor comprising an extracellular antibody variable domain specific for a ligand associated with the disease or disorder, a customizable spacer region, a transmembrane domain, and an intracellular signaling domain of a T-cell receptor or other receptors as described herein.
  • an adoptive cellular immunotherapy composition further comprises a chimeric receptor modified tumor-specific CD8+ cytotoxic T lymphocyte cell preparation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell preparation comprises CD8+ T-cells that have a chimeric receptor comprising an extracellular single chain antibody specific for a ligand associated with the disease or disorder, a customizable spacer region, a transmembrane domain, and an intracellular signaling domain of a T-cell receptor, as described herein.
  • an adoptive cellular immunotherapy composition comprises a chimeric receptor modified tumor-specific CD8+ cytotoxic T lymphocyte cell preparation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell preparation comprises CD8+ T-cells that have a chimeric receptor comprising an extracellular single chain antibody specific for a ligand associated with the disease or disorder, a customizable spacer region, a transmembrane domain, and an intracellular signaling domain of a T-cell receptor, in combination with an antigen-reactive chimeric receptor modified na ⁇ ve CD4+ T helper cell derived from CD45RO ⁇ CD62L+ and/or CD4+ T-cells, and a pharmaceutically acceptable carrier.
  • an adoptive cellular immunotherapy composition comprises an antigen specific CD8+ cytotoxic T lymphocyte cell preparation that provides a cellular immune response derived from the patient combined with an antigen-reactive chimeric receptor modified na ⁇ ve CD4+ T helper cell that augments the CD8+ immune response, wherein the helper T lymphocyte cell preparation comprises CD4+ T-cells that have a chimeric receptor comprising an extracellular antibody variable domain specific for the antigen associated with the disease or disorder, a customizable spacer region, a transmembrane domain, and an intracellular signaling domain of a T-cell receptor.
  • an adoptive cellular immunotherapy composition comprises an antigen-reactive chimeric receptor modified na ⁇ ve CD4+ T helper cell that augments the CD8+ immune response, wherein the helper T lymphocyte cell preparation comprises CD4+ T-cells that have a chimeric receptor comprising an extracellular antibody variable domain specific for a ligand associated with a disease or disorder, a customizable spacer region, a transmembrane domain, and an intracellular signaling domain of a T-cell receptor.
  • the CD4+ T helper lymphocyte cell is selected from the group consisting of na ⁇ ve CD4+ T-cells, central memory CD4+ T-cells, effector memory CD4+ T-cells, and bulk CD4+ T-cells.
  • CD4+ helper lymphocyte cell is a na ⁇ ve CD4+ T-cell, wherein the na ⁇ ve CD4+ T-cell comprises a CD45RO ⁇ , CD45RA+, CD62L+CD28+, CD27+, and/or CD4+.
  • the CD8+ T cytotoxic lymphocyte cell is selected from the group consisting of na ⁇ ve CD8+ T-cells, central memory CD8+ T-cells, effector memory CD8+ T-cells and bulk CD8+ T-cells.
  • the CD8+ cytotoxic T lymphocyte cell is a central memory T-cell wherein the central memory T-cell comprises a CD45RO+, CD62L+, CD27+, CD28+ and/or CD8+.
  • the CD8+ cytotoxic T lymphocyte cell is a central memory T-cell and the CD4+ helper T lymphocyte cell is a na ⁇ ve or central memory CD4+ T-cell.
  • the disclosure provides methods of making adoptive immunotherapy compositions and uses or methods of using these compositions for performing cellular immunotherapy in a subject having a disease or disorder.
  • Proliferation and persistence of the chimeric receptor modified T-cells can be determined by using an animal model of the disease or disorder and administering the cells and determining persistence and/or proliferative capacity of the transferred cells.
  • proliferation and activation can be tested in vitro by going through multiple cycles of activation with antigen bearing cells.
  • a method of manufacturing the compositions comprises obtaining a modified na ⁇ ve CD4+ T helper cell, wherein the modified helper T lymphocyte cell preparation comprises CD4+ T-cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a customized spacer domain, a transmembrane domain, and an intracellular signaling domain as described herein.
  • a method further comprises obtaining a modified CD8+ cytotoxic T cell, wherein the modified cytotoxic T lymphocyte cell preparation comprises CD8+ cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a customized spacer domain, a transmembrane domain, and an intracellular signaling domain as described herein.
  • a method comprises obtaining a modified CD8+ cytotoxic T-cell, wherein the modified cytotoxic T lymphocyte cell preparation comprises CD8+ T-cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a customized spacer domain, a transmembrane domain, and an intracellular signaling domain, as described herein, and further comprising combining the modified CD8+ cytotoxic T-cells with a CD4+ helper cell lymphocyte cell preparation.
  • Antigen specific T lymphocytes can be obtained from a patient having the disease or disorder or can be prepared by in vitro stimulation of T lymphocytes in the presence of antigen. Subpopulations of CD4+ and CD8+ T lymphocytes that are not selected for antigen specificity can also be isolated as described herein and combined in the methods of manufacturing. In some alternatives, the combination of cell populations can be evaluated for uniformity of cell surface makers, the ability to proliferate through at least two generations, to have a uniform cell differentiation status.
  • Quality control can be performed by co-culturing a cell line expressing the target ligand with chimeric receptor modified T-cells to determine if the chimeric receptor modified T-cells recognize the cell line using cytotoxicity, proliferation, or cytokine production assays that are known in the field.
  • Cell differentiation status and cell surface markers on the chimeric receptor modified T-cells can be determined by flow cytometry.
  • the markers and cell differentiation status on the CD8+ cells include CD3, CD8, CD62L, CD28, CD27, CD69, CD25, PD-1, CTLA-4, CD45RO, and/or CD45RA.
  • the markers and the cell differentiation status on the CD4+ cells include CD3, CD4, CD62L, CD28, CD27, CD69, CD25, PD-1, CTLA-4 CD45RO, and/or CD45RA.
  • the markers include CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L.
  • the markers include CD27, CD28 and/or CD62L.
  • Some alternatives relate to approaches for treating, inhibiting, or ameliorating a disease, such as cancer, such as ALL in a subject in need thereof, including methods of inhibiting or delaying progression and/or metastasis of a cancer, methods of inhibiting or reducing the presence of a tumor or cancer cell, and/or a methods of inhibiting or reducing a target population of CD19 expressing cells in a patient in need thereof.
  • Such methods involve administering to a subject or a patient in need thereof a genetically modified cytotoxic T lymphocyte cell preparation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell preparation comprises CD8+ T-cells that have a chimeric receptor comprising a polynucleotide coding for a ligand binding domain, wherein the ligand is a tumor specific antigen, or any other molecule expressed on a target-cell population (e.g.
  • CD19 that is suitable to mediate recognition and elimination by a lymphocyte; a polynucleotide coding for a polypeptide spacer wherein the polypeptide spacer is of a customized length, wherein the spacer provides for enhanced T-cell proliferation and/or cytokine production as compared to a reference chimeric receptor; a polynucleotide coding for a transmembrane domain; and a polynucleotide coding for one or more intracellular signaling domains.
  • a method comprises administering to the subject a genetically modified cytotoxic T lymphocyte cell preparation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell preparation comprises CD8+ T-cells that have a chimeric receptor comprising a ligand binding domain specific for a cell surface molecule, a customized spacer domain, a transmembrane domain, and an intracellular signaling domain as described herein, and a genetically modified helper T lymphocyte cell preparation that elicits direct recognition and augments the genetically modified cytotoxic T lymphocyte cell preparations ability to mediate a cellular immune response, wherein the helper T lymphocyte cell preparation comprises CD4+ T-cells that have a chimeric receptor comprising a ligand binding domain specific for a cell surface molecule, a
  • the chimeric receptor modified T-cell population that can persist and proliferate in vivo prior to administration can result in the ability to use a lower dose of T-cells and provide more uniform therapeutic activity.
  • the dose of T-cells can be reduced at least 10%, 20%, or 30% or greater. Reduction in the dose of T-cells can be beneficial to reduce the risk or tumor lysis syndrome and cytokine storm.
  • a method of performing cellular immunotherapy in subject having a disease or disorder comprises: administering to the subject a genetically modified helper T lymphocyte cell preparation, wherein the modified helper T lymphocyte cell preparation comprises CD4+ T-cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a customized spacer domain, a transmembrane domain, and an intracellular signaling domain as described herein.
  • the method further comprises administering to the subject a genetically modified cytotoxic T lymphocyte cell preparation, wherein the modified cytotoxic T lymphocyte cell preparation comprises CD4+ cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a customized spacer domain, a transmembrane domain, and an intracellular signaling domain as described herein.
  • Another alternative describes a method of performing cellular immunotherapy in a subject having a disease or disorder comprising: analyzing a biological sample of the subject for the presence of a target molecule (e.g. CD19) associated with the disease or disorder and administering the adoptive immunotherapy compositions described herein, wherein the chimeric receptor specifically binds to the target molecule (CD19).
  • a target molecule e.g. CD19
  • the CD4+ T helper lymphocyte cell is selected prior to introduction of the chimeric receptor from the group consisting of na ⁇ ve CD4+ T-cells, central memory CD4+ T-cells, effector memory CD4+ T-cells and bulk CD4+ T-cells.
  • CD4+ helper lymphocyte cell is a na ⁇ ve CD4+ T-cell, wherein the na ⁇ ve CD4+ T-cell comprises a CD45RO ⁇ , CD45RA+, CD28+, CD27+, CD62L+ and/or CD4+.
  • the CD8+ T cytotoxic lymphocyte cell is selected prior to introduction of the chimeric receptor from the group consisting of na ⁇ ve CD8+ T-cells, central memory CD8+ T-cells, effector memory CD8+ T-cells and bulk CD8+ T-cells.
  • the CD8+ cytotoxic T lymphocyte cell is a central memory T-cell wherein the central memory T-cell comprises a CD45RO+, CD62L+, CD28+, CD28+, and/or CD8+.
  • the CD8+ cytotoxic T lymphocyte cell is a central memory T-cell and the CD4+ helper T lymphocyte cell is a na ⁇ ve CD4+ T-cell.
  • the CD8+ T-cell and the CD4+ T-cell are both genetically modified with a chimeric receptor comprising an antibody heavy chain domain that specifically binds a cell surface molecule.
  • the intracellular signaling domain of the CD8 cytotoxic T-cells is the same as the intracellular signaling domain of the CD4 helper T-cells.
  • the intracellular signaling domain of the CD8 cytotoxic T-cells is different than the intracellular signaling domain of the CD4 helper T-cells.
  • the subjects that can be administered the alternatives described herein include humans, other primates, such as monkeys and apes, companion animals, such as dogs, cats, and horses, and domestic animals such as pigs, goats, sheep, and cattle.
  • the subjects can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects.
  • the methods are useful in the treatment of, for example, CD19 bearing cancer or cells.
  • Cells prepared as described above can be utilized in methods and compositions for adoptive immunotherapy in accordance with known techniques, or variations thereof that will be apparent to those skilled in the art based on the instant disclosure.
  • the cells are formulated by first harvesting them from their culture medium, and then washing and concentrating the cells in a medium and container system suitable for administration (a “pharmaceutically acceptable” carrier) in a treatment-effective amount.
  • a “pharmaceutically acceptable” carrier can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized.
  • the infusion medium can be supplemented with fetal calf serum.
  • Cells are then treated with cytokines to produce a transduced, cytokine-stimulated population of CD8+ T-cells and/or CD4+ T-cells with an increased or improved engraftment fitness as compared to non-cytokine stimulated populations of CD8+ T-cells and/or CD4+ T-cells.
  • the cytokines are desirably added in vitro during the propagation of the T-cells.
  • separated CD4+ and CD8+ T-cells are cytokine stimulated by the addition of cytokines during the propagation of the genetically modified T-cells.
  • the CD4+ T cells are stimulated with at least one cytokine, wherein the at least one cytokine comprises IL/7, IL-15 and/or IL-21.
  • the CD8+ T cells are stimulated with at least one cytokine, wherein the at least one cytokine comprises IL-2, IL-15 and/or IL-21.
  • a treatment or inhibitory effective amount of cells in the composition is at least 2 cell subsets (for example, 1 CD8+ central memory T-cell subset and 1 CD4+ helper T-cell subset) or is more typically greater than 10 2 cells, and up to 10 6 , up to and including 10 8 or 10 9 cells and can be more than 10 10 cells or any other value in a range defined by any of these two values.
  • the number of cells will depend upon the ultimate use for which the composition is intended as will the type of cells included therein. For example, if cells that are specific for a particular antigen are desired, then the population will contain greater than 70%, generally greater than 80%, 85% and/or 90-95% of such cells.
  • the cells are generally in a volume of a liter or less, can be 500 mls or less, even 250 mls or 100 mls or less, or any other value within a range defined by any two of these values.
  • the density of the desired cells is typically greater than 10 4 cells/ml and generally is greater than 10 7 cells/ml, generally 10 8 cells/ml or greater.
  • the clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 10 6 , 10 7 , 10 8 , 10 9 , 10 10 or 10 11 cells or any other amount within a range defined by any of these two values.
  • the lymphocytes of the invention can be used to confer immunity to individuals.
  • immuno is meant a lessening of one or more physical symptoms associated with a response to infection by a pathogen, or to a tumor, to which the lymphocyte response is directed.
  • the amount of cells administered is usually in the range present in normal individuals with immunity to the pathogen.
  • the cells are usually administered by infusion, with each infusion in a range of from 2 cells, up to at least 10 6 to 3 ⁇ 10 10 cells, preferably in the range of at least 10 7 to 10 9 cells.
  • the T-cells can be administered by a single infusion, or by multiple infusions over a range of time.
  • T lymphocytes including cytotoxic T lymphocytes and/or helper T lymphocytes
  • the rapid expansion method of the present invention See, e.g., U.S. Pat. No. 6,040,177 to Riddell et al. at column 17, hereby expressly incorporated by reference in its entirety.
  • compositions, as described herein are administered intravenously, intraperitoneally, intratumorly, into the bone marrow, into the lymph node, and/or into cerebrospinal fluid.
  • compositions, as described herein are administered with chemotherapeutic agents and/or immunosuppressants.
  • a patient is first administered a chemotherapeutic agent that inhibits or destroys other immune cells followed by the compositions described herein. In some cases, chemotherapy can be avoided entirely.
  • CD4 and CD8 T cell subsets were immunomagnetically isolated from apheresis products obtained from the research participant. Following anti-CD3 ⁇ CD28 bead stimulation, T cell lines were transduced with a SIN lentiviral vector that directs the co-expression of the FMC63scFv:IgG4hinge: CD28tm:4-1BB: ⁇ CAR and the selection and tracking suicide construct EGFRt. Transduced cells were propagated using recombinant human cytokines to numbers suitable for clinical use over 10-20 days during which time they were subjected to EGFRt immunomagnetic positive selection.
  • the enriched CD4+ expressing T-cells were contacted, for example propagated, in 5 ng/mL recombinant human IL-7 (rhIL-7) and/or 0.5 ng/mL recombinant human IL-15 (rhIL-15).
  • the enriched CD8+ expressing T-cells were contacted, for example propagated, in 50 U/mL recombinant human IL-2 (rhIL-2) and/or 0.5 ng/mL recombinant human IL-15 (rhIL-15).
  • Each of the twelve responding subjects developed some degree of CRS with fever and hypotension as the hallmark symptoms.
  • sCRS tocilizumab for two, and addition of dexamethasone in one.
  • encephalopathy 2 grade 1, 1 grade 3 and 1 grade 4.
  • the grade 4 encephalopathy was a DLT, and accompanied by seizures and abnormal MRI findings similar to PRES. MRI findings were normalized by 9 weeks post therapy, but the subject, at the time of last assessment, continued to have seizures, 6 months from therapy.
  • infusions of prescribed dose levels of defined composition CD4:CD8 CD19CAR/EGFRt+ T cells/kg produced encouraging rates of MRD-negative CRs in pediatric and young adult ALL patients who have suffered a post-HSCT relapse.
  • the expected toxicities for the 13 evaluable patients include CRS with ⁇ 30% ICU admission rate and encephalopathy with severity ranging from mild to severe. MRD negative responses have been seen at all dose levels, although early data suggests enhanced persistence at escalating doses.
  • the preliminary assessment suggested that CAR T cells were not mediators of this response.
  • prednisone did not affect persistence of the T cell graft.
  • the cells that maintained the markers CD28, CD27, and CD62L showed high persistence in comparison to cells that were not treated with the defined cytokine mixtures and lack the markers for engraftment fitness, which are the T-cells that are used for the current method of treatment.
  • FIG. 18 is a flow diagram depicting the development history of a process used to manufacture the genetically modified T-cell comprising a chimeric antigen receptor. As indicated, the current manufacturing procedure does not have the Ficoll processing, whereas initial experimental processes included a Ficoll processing step. The initial variations of cell concentrations were also tested as shown in the flow diagram of FIG. 19 . Cells were also expanded in the presence of cytokines ( FIG. 20 ).
  • donor sample PD0064 PD0063 CD8+ enriched T-cells were used to test starting cell density in a T25 flask on initiation. Both cells (from PD0064, PD0063) were tested under normal PLAT-02 culture conditions, IL-2 (50 U/ml)+IL-15 (0.5 ng/mL). Cells from donor sample PD0080, were used in a study to test the expansion of cells on Tx day, by adding media and cytokines for a final cell concentration of to 0.7 ⁇ 10 ⁇ 6 cell/mL (“early expansion”).
  • Tx it is meant throughout to refer to Day +1, based on the day of stimulation beads being defined as Day +0.
  • volume up refers to the volume of media/cytokine addition for initial feeding following Tx was greater in the “early expansion” conditions, leading to decreased cell density at this point in culture for “early expansion” conditions.
  • PD0104 PD0063 CD8+ and CD4+ enriched cells were used to repeat previous experiments to test the expansion of cells on Tx day to 0.7 ⁇ 10 6 cell/mL (“early expansion”), with the following cytokines and respective concentrations being added: IL-2 (50 U/ml)+IL-15 (0.5 ng/mL) for CD8+ T ⁇ cells and IL-7 (5 ng/mL)+IL-15 (0.5 ng/mL) for CD4+ T-cells. Growth and viability were increased dramatically. These curves mimic what was seen in clinical products as far as timing of growth/bead removal/selection/cryopreservation.
  • the PD0116 PD0046 CD8+ and CD4+ enriched cells were used to repeat the experiment to test the expansion of cells on Tx day to 0.7 ⁇ 10 ⁇ 6 cell/mL (“early expansion”).
  • Normal PLAT-02 culture conditions IL-2 (50 U/ml)+IL-15 (0.5 ng/mL) for CD8 cells and IL-7 (5 ng/mL)+IL-15 (0.5 ng/mL) for CD4's.
  • PD116 was initiated at 180 ⁇ 10 ⁇ 6 cells in a V-197 bag and magnetic enrichment and spinoculation were performed in a transfer pack. As shown, from these conditions, growth and viability were increased dramatically. These curves mimic what was seen in clinical products as far as timing of growth, bead removal, selection, and cryopreservation of T-cells.
  • PD0116 PD0046 CD8+ and CD4+ enriched cells were also used to repeat an experiment to test the expansion of cells on Tx day by the addition of media and cytokines for a final volume of to 0.7 ⁇ 10 6 cell/mL (“early expansion”).
  • Normal PLAT-02 culture conditions in which additions of IL-2 (50 U/ml)+IL-15 (0.5 ng/mL) for CD8 cells and IL-7 (5 ng/mL)+IL-15 (0.5 ng/mL) for CD4's was performed.
  • PD116 was initiated at 180 ⁇ 10 6 cells in a V-197 bag and magnetic enrichment and spinoculation were performed in a transfer pack. This was the full scale data used to transition to an updated manufacturing process. As shown in the FIG.
  • CD8+ cells growth expansion was increased for CD8+ cells in comparison to the CD4+ cells.
  • the cytokines used for the CD4 — and the CD8+ cells and the variations of the combinations of the cytokines used are depicted in a flow chart as shown in FIG. 22 .
  • the PD0047: PD0038 CD8+ enriched cells were used to test various cytokine cocktails.
  • the same cytokine cocktails were tested using “low dose” IL-2 at 10 U/mL final.
  • Concentrations of the individual cytokines used in the various combinations were: IL-2 (50 U/mL) and (10 U/mL) as stated in the legend, IL-7 (5 ng/mL), IL-15 (0.5 ng/mL), IL-21 (5 ng/mL).
  • Pulse conditions were an IL-2 pulse for 5 days followed by IL-7/IL-21 throughout the remainder of the culture. Fold growth and TNC are extrapolated from a small scale experiment.
  • the IL-2/IL-15 combination showed the best expansion and was used for following experimentations.
  • Panel A shows results from incubation of PD0047 cells at day 15 (D15) and the comparison of growth with various cytokines and the percent positive cells (CD3+, CD62L+, CD3+/CD62L+/CD45RO ⁇ , CD28+, CDD45RA+/CD4RO ⁇ , CD45RA+/CD45RO and CD45RA ⁇ /CD45RO+), following incubation with the various cytokine conditions.
  • Panel B shows results following incubation of PD0047 cells at day 21 (D21) and the comparison of growth with various cytokines and the percent positive cells as indicated above.
  • Panel C shows PD0040 D21 and the comparison of growth with various cytokines, in which the total cell number is examined after 22 days of growth in culture.
  • Panel D shows PD0040 D21 and the comparison of growth with various cytokines, as indicated the CD3+ cell growth is examined after 22 day of culture growth.
  • Panel E shows PD0047 and the comparison of growth with various cytokines, in which the total cell number is examined after 22 days of growth in culture.
  • Panel F shows PD0047 and the comparison of growth with various cytokines, as indicated the CD3+ cell growth is examined after 22 day of culture growth.
  • PD0038 CD8+ enriched cells were used to test various cytokine cocktails. Concentrations for each condition were: IL-2 (50 U/mL), IL-7 (5 ng/mL), IL-15 (0.5 ng/mL). Condition #4 was an IL-2 pulse for 5 days followed by IL-7/IL-15 throughout the remainder of the culture. Fold growth and TNC were extrapolated from small scale experiments. IL-2/IL-15 combination showed the best expansion and was used for future experiments. Additionally, PD0047: PD0038 CD8+ enriched cells were used to test various cytokine cocktails. The same cytokine cocktails were tested using “low dose” IL-2 at 10 U/mL final.
  • IL-2 50 U/mL
  • IL-7 5 ng/mL
  • IL-15 0.5 ng/mL
  • IL-21 5 ng/mL
  • Pulse conditions were an IL-2 pulse for 5 days followed by IL-7/IL-21 throughout the remainder of the culture. Fold growth and TNC were then extrapolated from small scale experiments.
  • the IL-2/IL-15 cytokine combination used in the study described above showed the best expansion.
  • the “normal” dose of IL-2 also showed the best growth. Flow cytometry for phenotypic growth is available and indicated in further experiments herein.
  • FIG. 24 Shown in FIG. 24 , are results from a series of experiments to test the different combination of cytokines PD0051: CD8+ cells from two different donors were used to test the “normal” cytokine conditions using IL-2 (50 U/mL) and IL-15 (0.5 ng/mL) were used. Pulse conditions were an IL-2 pulse for 5 days followed by IL-7 (5 ng/mL), IL-21 (5 ng/mL), throughout the remainder of the culture. Fold growth and TNC that are shown, are from a scaled experiment that started with 30 ⁇ 10 ⁇ 6 cells. The currently used IL-2/IL-15 combination showed the best expansion, but expansion was also seen from the cultures pulsed with IL-2 and switched to IL-7/IL-21. Fold expansion was similar in the pulsed conditions to PD0047.
  • Cytokine conditions were IL-7 (5 ng/mL) and IL-15 (0.5 ng/mL) for the experiments.
  • Pulse conditions were an IL-2 pulse for 5 days followed by IL-7 (5 ng/mL), IL-21 (5 ng/mL), throughout the remainder of the culture. Fold growth and TNC are from a scaled experiment that started with 30 ⁇ 10 ⁇ 6 cells.
  • the currently used IL-7/IL-15 combination showed the usual expansion, however better expansion was seen from the cultures pulsed with IL-2 and switched to IL-7/IL-21.
  • Panel A shows PD0051 at day 15 (D15) and the comparison of growth with various cytokines and the percent positive cells (EGFRt+, EGFRt+/CD4+, EGFRt+/CD8+, CD3+, CD3+/CD4+, CD3+/CD4+/CD8+, CD3+/CD8+, CD62L+, CD3+/CD8+, CD62L+, CD3+/CD28+, CD27+, CD127+, CD45RA+/CD45RO ⁇ , CD45RA+/CD45RO_/CD45RO_/CD45RA ⁇ , CD62+/CD28+) in a donor versus donor cytokine comparison.
  • Panel B shows PD0055 at day 17 (D17) and the comparison of growth with various cytokines and the percent positive cells.
  • Panel C shows the PD0051 growth curve and the comparison of growth with various cytokines, in which the total cell number is examined after 20 days of growth in culture.
  • Panel D shows PD0051 and the comparison of growth with various cytokines, as indicated the CD3+ cell growth is examined after 20 days of culture growth.
  • Panels C and D show a growth curves (total cells and CD3+) for PD0051, comparing growth following incubation of the cells with the indicated various cytokines, through 20 days in culture.
  • Panel E and F shows growth curves (total cells and CD3+ respectively) for donor PD0055 following incubation with the indicated various cytokines, at the indicated time point at day 17 of growth in culture.
  • FIG. 25 Shown in FIG. 25 , is a cytokine testing experiment in which different combinations of cytokines were evaluated for their influence on cell expansion.
  • the same cytokine testing experiment as shown for PD0051 was performed except that this experiment involved testing a new CD4+ and CD8+ donor (PD0057).
  • Testing the “normal” cytokine conditions using IL-7 (5 ng/mL) and IL-15 (0.5 ng/mL) for CD4's and IL-2 (50 U/mL) and IL-15 (0.5 ng/mL) for CD8+ cells were performed. Pulse conditions were an IL-2 pulse for 5 days followed by IL-7 (5 ng/mL), IL-21 (5 ng/mL), throughout the remainder of the culture. Fold growth and TNC are from a scaled experiment that started with 30 ⁇ 10 6 cells.
  • the “normal” cytokine combinations in this study resulted in expansion; good expansion was seen following pulsing with IL-2 and switching to IL-7/IL
  • cytokine study was performed as in PD0051, except that the experiment was performed with a different CD4+ and CD8+ donor (PD0063).
  • the test was performed using “normal” cytokine conditions using IL-7 (5 ng/mL) and IL-15 (0.5 ng/mL) for CD4's and IL-2 (50 U/mL) and IL-15 (0.5 ng/mL) for CD8's versus an IL-2 only condition. All growth through day 14 (D+14) was on a normal plane, cultures were then EGFRt selected. Recovery of viability and growth was not seen following selection for the CD8+ cells. As shown in Panel A, are the percent of positive cells after thawing the cells.
  • Panel B shows the PD0059 PLAT-02 cytokine comparison.
  • Panel C shows PD0059 PLAT-02 cytokine comparison and the CD3+ cell growth.
  • Panel D shows the PD0078 growth curves.
  • Panel D shows the PD0078 growth curves and the CD3+ cell growth.
  • FIG. 26 Shown in FIG. 26 , are two flow charts illustrating an initial expansion methodology and the updated (or “current”) expansion methodology of cell expansion based on experimentation, which was then used for future experimentations.
  • FIG. 27 Shown in FIG. 27 , are growth curves for samples from PD0080, PD0084, and PD0085 and a comparison between all three. These three experiments were repeated experiments of the “early expansion” methodology. For these experiments, the standard cytokine conditions were used: IL-2 (50 U/mL)+IL-15 (0.5 ng/mL) for CD8+ T-cells and IL-7 (5 ng/mL)+IL-15 (0.5 ng/mL) for CD4+ T-cells.
  • IL-2 50 U/mL
  • IL-7 5 ng/mL
  • IL-15 0.5 ng/mL
  • PD0084 two additional CD8+ donor T-cells were assessed for effects of early expansion. 30 ⁇ 10 6 cell starting conditions were used as a control for each donor and a 60 ⁇ 10 6 cell starting density was used with early expansion as test conditions. For PD0085, a similar test to PD0084 was performed except the CD4+ T-cells were used to test early expansion. Again 30 ⁇ 10 6 starting cell density were used as “normal” control condition and 60 ⁇ 10 6 cell starting density was used as a test condition.
  • the starting material of PD0038 included selected CD4+ and CD8+ T-cells.
  • the growth curves show TNC from both V-197 bags of cells that were pooled together. From the early development, it was intended to pool to 50:50 CD4:CD8 product prior to cryopreservation. Flow data shows post thaw of the pooled product. Bead removal and EGFRt enrichment occurred D+14 for CD4+ and D+15 for CD8+ T-cells.
  • CD8+ T-cells were grown in IL-2 (50 U/mL)/IL-15 (0.5 ng/mL) and CD4+ T-cells were grown in IL-7 (5 ng/mL)/IL-15 (0.5 ng/mL). This process was changed to a cryopreservation of separate products and infusing a 50:50 product upon thawing.
  • FIG. 29 Shown in FIG. 29 , is the growth curve for PD0046. Growth curves show TNC from both V-197 bags of cells together. In early development there was an intent to pool a 50:50 CD4:CD8 product prior to cryopreservation. Flow data shows post thaw of the pooled product. Bead removal and EGFRt enrichment then occurred. D+14 for CD4+ T-cells and D+15 for CD8+ T-cells. CD8+ T-cells were grown in IL-2 (50 U/mL)/IL-15 (0.5 ng/mL) and CD4+ T-cells were grown in IL-7 (5 ng/mL)/IL-15 (0.5 ng/mL). However, not much was done following this product, due to the donor cells thawing poorly. Cells were used later to test 10% HA thawing and proved to be much better.
  • FIG. 30 Shown in FIG. 30 , is the growth curve for PD0063. Growth curves show TNC from both V-197 bags of cells together. Bead removal and EGFRt enrichment then occurred D+14 for CD4's and D+15 for CD8's are shown. CD8+ cells were grown in IL-2 (50 U/mL)/IL-15 (0.5 ng/mL) and CD4+ cells were grown in IL-7 (5 ng/mL)/IL-15 (0.5 ng/mL). Bead removal and EGFRt enrichment then occurred.
  • IL-2 50 U/mL
  • IL-15 0.5 ng/mL
  • IL-7 5 ng/mL
  • IL-15 0.5 ng/mL
  • FIG. 31 Shown in FIG. 31 , is the expansion of cells from bulk PBMC cultures when grown in the presence of cytokines. As shown, CD4+ cells ( ⁇ ) were grown in the presence of IL2 and IL15. CD8+ cells ( ⁇ ) were grown in the presence of IL7 and IL15.
  • the lower panel, (phenotypic comparison) of FIGS. 31A and 31B shows percentage of total cells expressing the indicated markers on their surfaces following incubation with the different conditions, each of which resulted in cells expressing markers of engraftment fitness, e.g., CD62L, CD28, CD27, CD45RA.
  • Growing CD8-enriched cultures in IL-2/IL-15 and CD4-enriched cultures in IL-7/IL-15 yielded robust expansion of both cultures and strong expression of memory phenotype.
  • FIG. 32 Shown in FIG. 32 , is the expansion of enriched CD8+ and CD4+ cells in cytokine mixtures.
  • enriched CD8+ T-cells were expanded in the presence of IL2 and IL15 (top panel).
  • enriched CD4+ T-cells were expanded in the presence of IL7 and IL15 for over 20 days.
  • the pooled CD4+ and CD8+ T-cells expressed CD3, CD4, CD8, CD62L, CD28, CD27, CD45RA and CD45RO. Also tested was sample 14602-S14 (See FIG. 32B ).
  • CD4+ T-cells and CD8+ T-cells grew optimally with different cytokine combinations such that CD4+ T-cells performed best in these studies with IL7 and IL15, while CD8+ T-cells grew best in these studies with the cytokines IL2 and IL15.
  • FIG. 33 Shown in FIG. 33 , are samples from 14602-S01 through 14602-S06 using the original PLAT-02 (Phase I and Phase II of clinical trials) methodology of cell expansion.
  • the cells were positive for EGFRt prior to cyropreservation.
  • the cells were tested for viability.
  • the cells 14602-S03 CD8+ and 14602-S03-CD8+ cells did not express CD3, CD62L, CD27, CD127, CD45RA/CD45RO ⁇ or CD45RA.
  • FIG. 34 are tests on the cell product 14602-SO4 and 14602-SO4-02 which have both CD4+ and CD8+ T-cells.
  • the cells were grown in cultures using the “early expansion” methodology.
  • the cells were tested positive for EGFRt expression prior to cryopreservation.
  • FIG. 35 Shown in FIG. 35 , are the cells from samples 14602-S07, 14602-S08, and 14602-S09.
  • the CD4+ and CD8+ cells were expanded using the early expansion methodology.
  • the top panel as shown in the table for 14602-S07 CD4+, cells and 14602-S07 CD8+ cells, shows percentage of cells expressing various markers including CD3, CD62L, CD27, CD27, CD127, and CD45RA+ at various times.
  • CD4+ and CD8+ enriched T-cells remained viable after 10 days in culture.
  • FIG. 36 Shown in FIG. 36 , are the cells tested for viability from the batch samples of 14602-S10, 14602-S11, 14602-S12 and 14602-S13. As shown in the accompanying tables, the cells all expressed EGFRt prior to cryopreservation. The cells were tested for viability in cell culture for at least 12 days.
  • FIG. 37 Shown in FIG. 37 , are the cells tested for viability from the batch samples of 14602-S14, 14602-S15 and 14602-S16. As shown in the accompanying tables, the cells all expressed EGFRt prior to cryopreservation. The cells were tested for viability in cell culture for at least 12 days.
  • the cells from the sample of 14602 which CD4+ and CD8+ T-cells were enriched from, were positive for CD3, CD62L, CD28, CD127, CD45RA+/CD45RO ⁇ , CD45RA and CD45RO. These are specific markers which to indicate that both CD4+ and CD8+ cells had a high level of engraftment fitness following the treatment with their specific cytokine combinations.
  • FIG. 39 Shown in FIG. 39 , are the results for a mouse after T-cell administration after tumor inoculation (survival, tumor progression). As shown, the mouse injected with the cells from the sample PD0046 indicated that the cells had a high, improved, or enhanced engraftment fitness due to the survival of the mouse after 80 days of administration using multiple concentrations of cells. The sample PD00044 did not have a high, improved, or enhanced engraftment fitness as the percent survival dropped at day 40 ( FIG. 39B ).
  • FIG. 40 is the average tumor progression in mice treated with cells from the PD0044 and PD0046 cell batches.
  • the tumor progression in the mouse decreased if they were administered the CD8+ and CD4+ T-cells from the PD0046 batch, in which the cells were originally grown in the appropriate cytokine mixtures for CD4+ and CD8+ T-cells (IL7/IL15 for CD4+ T-cells and IL2/IL15 for CD8+ T-cells).
  • the vehicle cells did not halt tumor progression in either study with PD0044 and PD0046.
  • tumor progression increased in mice treated with cells from the PD0044 sample, and in particular increased substantially when treated with the least concentration of T-cells. Tumor progression decreased in comparison to the vehicle control.
  • mice were tested in which each group had a total number of 5 mice per group.
  • Group A the mice were treated with a placebo of phosphate buffered saline (PBS).
  • Group B utilized cells from “normal” expansion” which had a 1:1 EGFRt+CD4:CD8 transduced with Zrx-014.
  • the cells used were from group PD0055 #1 (Donor PD0038 CD4 with 5 ng/ml IL7 & 0.5 ng/ml IL15, S1D14 at 75.9% EGFRt+) and group PD0051 #1 (Donor PD0038 CD8 with 50 U/ml IL2 & 0.5 ng/ml IL15, S1D21 @ 76.8% EGFRt+)
  • Group C utilized cells that were “pulsed” with cytokine treatments which comprised 1:1 EGFRt+CD4:CD8 transduced with Zrx-014 PD0055 #2 (Donor PD0038 CD4 with 50 U/ml IL2 pulse 5 days, then 5 ng/ml IL7 & 5 ng/ml IL21, S1D11 at 81.2% EGFRt+) PD0051 #2 (Donor PD0038 CD8 with 50 U/ml IL2 pulse 5 days, then 5 ng/ml IL7 &
  • FIG. 42 are the FACS analysis on cells post thaw that were used for injection into mice in JME13-25 (PD0051 and PD00055 cells). As shown both samples of cells had CD8+ and CD4+ T-cells that expressed EGFRt.
  • mice As shown in FIG. 43 , are the three groups of mice from groups A, B, and C that were treated with placebo PBS (group A), group B (PD00051 “normal expansion cells”) and group C (PD00055, cells pulsed with cytokine combinations).
  • group A groups of mice from groups A, B, and C that were treated with placebo PBS
  • group B group B
  • PD00051 “normal expansion cells”
  • group C PD00055, cells pulsed with cytokine combinations.
  • mice that were treated with the placebo in Group A had tumor progression that is visibly seen at day 20.
  • mice treated with PD0051 normal expansion cells
  • the mice it is shown that tumor progression increases in two mice substantially.
  • mice the mice treated with PD00055 show only a small amount of tumor progression, therefore indicating the cells treated with the cytokine mixture prior to use in treatment had a higher engraftment fitness.
  • the persistence of the CAR expressing T-cells in the mice after three days of administration is the persistence of the CAR expressing T-cells in the mice after three days of administration.
  • the CD4+ T-cells expressing the CARs had a higher persistence compared to the cells of normal expansion as well as the CD8+ T-cells.
  • mice were treated with a placebo (PBS).
  • Group B were treated with cells that were expanded by the “normal expansion method” (“Normal” 1:1 EGFRt+ CD4:CD8 transduced with Zrx-014 PD0055 #1 (Donor PD0038 CD4 with 5 ng/ml IL7 & 0.5 ng/ml IL15, S1D14 @ 75.9% EGFRt+) PD0051 #1 (Donor PD0038 CD8 with 50 U/ml IL2 & 0.5 ng/ml IL15, S1D21 @ 76.8% EGFRt+) ( FIG. 18 ).
  • Normal Normal 1:1 EGFRt+ CD4:CD8 transduced with Zrx-014 PD0055 #1 (Donor PD0038 CD4 with 5 ng/ml IL7 & 0.5 ng/ml IL15, S1D14 @ 75.9% EGFRt+)
  • PD0051 #1 Donor PD0038 CD8 with 50 U/ml IL2 & 0.5 ng/
  • Group C were treated with cells pulsed with cytokines during expansion (“Pulsed” 1:1 EGFRt+CD4:CD8 transduced with Zrx-014 PD0055 #2 (Donor PD0038 CD4 with 50 U/ml IL2 pulse 5 days, then 5 ng/ml IL7 & 5 ng/ml IL21, S1D11 at 81.2% EGFRt+) PD0051 #2 (Donor PD0038 CD8 with 50 U/ml IL2 pulse 5 days, then 5 ng/ml IL7 & 5 ng/ml IL21, S1D21 at 89.5% EGFRt+).
  • group A mice died by day 20 following injection with PBS.
  • Group B mice treated with cells that were expanded by the “normal expansion method” had tumor progression in one mouse by day 120.
  • the mice were tumor free by day 120.
  • the data indicate that the cells treated in the cytokine mixtures specific for CD4+ and CD8+ led to a higher engraftment rate and increased survival in the mice. Additionally, the cells were more efficient in preventing tumor progression.
  • mice had a 100% survival rate when treated with PD0051 and PD0055 cells post tumor inoculation. However, the tumor progression was shown to decrease with the treatment using PD0055 cells.
  • mice were tumor inoculated and imaged for tumors at day 6. At day 7, T-cells or a placebo was then administered. Tumor inoculation was then repeated at day 14 and day 21.
  • mice were examined for tumor progression at day 28, 35, 49, 63, 78, 92, 105 and 120, in which images of the tumors were taken. As shown in the groups of mice, tumor progression decreased in the mice treated with the cells that were pulsed with cytokines thus indicating that the cells pulsed with cytokines had a higher, improved, or enhanced engraftment fitness than the cells that were expanded under normal conditions without cytokines.
  • mice were used test the cells in the treatment of mice after tumor inoculation. The groups were given a dose of cells (1.25 ⁇ 10 6 , 2.5 ⁇ 10 6 , 5 ⁇ 10 6 , 10 ⁇ 10 6 ) per product condition as indicated on the Table of FIG. 49 . The cells were thawed, counted and injected into the mice on the same day. As shown in FIG. 50 , are the amounts of CD4+ and CD8+ cells in the different cell products from the two expansion methods and their amounts of EGFRt in the cells.
  • mice that were dosed with PLAT-1.00 cells at the higher concentrations had a decrease in tumor progression.
  • mice that were dosed with PLAT-2.00 also saw a decrease in tumor progression after 25 days of administration at a higher concentration of cells.
  • the mice saw an increase in tumor progression regardless of cell concentration indicating a low or reduced engraftment fitness for these cells.
  • the mice had a decrease in tumor progression when treated with the highest concentration of cells in the administration.
  • the cells of PLAT-1.33 also had a low EGFRt count which could also indicate a decreased amount of CAR on the cell surface.
  • FIG. 51 Shown in the FIG. 51 , is the initiation comparisons between the PD104 and the PD116 cell product.
  • PD0063 CD8+ and CD4+ enriched cells were used to repeat experiment to test the expansion of cells on Tx day to 0.7 ⁇ 10 6 cell/mL (“early expansion”).
  • IL-2 50 U/ml
  • IL-15 0.5 ng/mL
  • IL-7 5 ng/mL
  • IL-15 0.5 ng/mL
  • mice were treated with dose titrations of cell products of PLAT-1.00, PLAT-1.33, PLAT-1.67 and PLAT-2.00. As shown in all graphs, the lowest concentration of cells was least effective in the treatment of tumor progression. However, the cells that showed the most engraftment fitness were the PLAT-1.00 and the PLAT-2.00 at higher concentration.
  • all the cells were least effective at concentration 1.25 ⁇ 10 6 .
  • the cells from PLAT-1.00 showed to be the most effective at inhibiting tumor progression indicating that the engraftment fitness of the cells were superior or improved, or enhanced as compared to the other groups and indicated that the treatment with cytokines also promoted, improved, or enhanced engraftment fitness for the cells.
  • the tumor progression was halted at 25 days in comparison to the other groups of cells used to treat the mice.
  • mice had a higher rate of survival if treated with a dose of cells between 2.5 ⁇ 10 6 and 10 ⁇ 10 6 cells per dose.
  • the mice treated with the cells from the PLAT-1.00 product had a longer survival rate indicating that the T-cells from this group were more robust and exhibited a higher, improved, or enhanced engraftment fitness.
  • the survival of the mice was dependent on the dose concentration of the cells. For all cells, the survival of the mice decreased with the lowest dose of T-cell treatments. However, as previously shown the mice treated with the cells from the PLAT-1.00 product had a longer survival rate indicating that the T-cells from this group were more robust and had an improved engraftment fitness.
  • a method of making genetically modified T-cells, which have a chimeric antigen receptor comprises separating, isolating, or enriching a CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, so as to generate an isolated population of T-cells, stimulating the obtained population of T-cells so as to generate a stimulated population of CD8+ T-cells and/or CD4+ T-cells, transducing the stimulated population of CD8+ T-cells and/or CD4+ T-cells with a vector, wherein the vector encodes a chimeric antigen receptor and a marker sequence, wherein said marker sequence encodes a cell surface selectable marker, so as to generate a transduced population of CD8+ T-cell
  • the separating of the CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells is performed by affinity selection for T-cells having an epitope present on CD8 and/or CD4. In some alternatives, the separating of the CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells is performed by flow cytometry. In some alternatives, the separating of the CD8+ population of T-cells and/or a CD4+ population of T-cells from a mixed population of T-cells is performed by immuno-magnetic selection.
  • the genetically modified CD8+ T-cells and/or CD4+ T-cells comprise at least one receptor that promotes engraftment fitness.
  • the at least one receptor is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L.
  • the at least one receptor is CD27, CD28 and/or CD62L.
  • the stimulating of the isolated population of T-cells is performed by contacting the CD8+ and/or CD4+ T-cells with an antibody-bound support, such as a bead or particle.
  • the antibody-bound support comprises anti-TCR, anti-CD2, anti-CD3, anti-CD4 and/or anti-CD28 antibodies. In some alternatives, the antibody-bound support comprises anti-CD3 and/or anti-CD28 antibodies.
  • the vector further comprises a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the vector further comprises a sequence encoding a spacer. In some alternatives, the spacer comprises an IgG4 hinge. In some alternatives, the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector.
  • the viral vector is a lentivirus vector.
  • the marker sequence encodes a truncated epidermal growth factor receptor (EGFRt).
  • the at least one cytokine comprises GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-2, and/or IL-21.
  • the at least one cytokine comprises IL/7, IL-15 and/or IL-21. In some alternatives, the at least one cytokine comprises IL-2, IL-15 and/or IL-21. In some alternatives, the contacting is performed for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or a period of time within a range defined by any two of these values. In some alternatives, the method is performed with isolated CD4+ cells in the absence of CD8+ cells. In some alternatives, the method is performed with isolated CD8+ in the absence of or enriched over CD4+ cells.
  • the CD4+ expressing T-cells are propagated for at least 1 day and may be propagated for 20 days, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or for a period that is within a range defined by any two of the aforementioned time periods.
  • the CD8+ expressing T-cells are propagated for at least 1 day and may be propagated for 20 days, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or for a period that is within a range defined by any two of the aforementioned time periods.
  • the method further comprises removing the antibody-bound support, such as beads or particles.
  • the ligand binding domain of the chimeric antigen receptor comprises an antibody, or a binding portion thereof. In some alternatives, the ligand binding domain of the chimeric antigen receptor comprises a single chain variable fragment (scFv), or a binding portion thereof. In some alternatives, the ligand binding domain of the chimeric antigen receptor comprises FMC63, or a binding portion thereof. In some alternatives, the ligand binding domain of the chimeric antigen receptor is specific for CD19. In some alternatives, the method further comprises cryopreserving the genetically modified CD8+ and/or CD4+ T-cells.
  • a population of genetically modified T-cells comprising a plurality of affinity selected CD8+ and/or CD4+ T-cells, in the absence of, enriched over, or isolated from CD8 ⁇ and/or CD4 ⁇ T-cells, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells have stimulated CD2, CD3, CD4 and/or CD28 receptors, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise a gene encoding a chimeric antigen receptor and a cell surface selectable marker and, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells have been re-stimulated with at least one cytokine.
  • the at least one cytokine comprises GM-CSF, IL-7, IL-12, IL-18, IL-15, IL-2, and/or IL-21. In some alternatives, the at least one cytokine comprises IL/7, IL-15 and/or IL-21. In some alternatives, the at least one cytokine comprises IL-2, IL-15 and/or IL-21. In some alternatives, the said plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise at least one receptor that promotes, induces, contribute to or enhances engraftment fitness.
  • the at least one receptor that promotes, induces, contribute to or enhances engraftment fitness is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L. In some alternatives, the at least one receptor that promotes, induces, contribute to or enhances engraftment fitness is CD27, CD28 and/or CD62L. In some alternatives, the plurality of affinity selected CD8+ and/or CD4+ T-cells further comprises a vector having a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the vector further comprises a sequence encoding a spacer.
  • the spacer comprises an IgG4 hinge.
  • the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector.
  • the viral vector is a lentivirus vector.
  • the cell surface selectable marker encodes for a truncated epidermal growth factor receptor (EGFRt).
  • the ligand binding domain comprises an antibody, or a binding portion thereof. In some alternatives, the ligand binding domain comprises a single chain variable fragment (scFv), or a binding portion thereof. In some alternatives, the ligand binding domain comprises FMC63, or a binding portion thereof. In some alternatives, the ligand binding domain is specific for CD19. In some alternatives, the population comprises isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells. In some alternatives, the population comprises isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells.
  • a composition or product combination for human therapy comprising a pharmaceutical excipient and at least one population of genetically modified T-cells.
  • the at least one population of genetically modified T-cells comprises a plurality of affinity selected CD8+ and/or CD4+ T-cells, in the absence of, enriched over, or isolated from CD8 ⁇ and/or CD4 ⁇ T-cells, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells have stimulated CD2, CD3, CD4 and/or CD28 receptors, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise a gene encoding a chimeric antigen receptor and a cell surface selectable marker and, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells have been re-stimulated with at least one cytokine.
  • the at least one cytokine comprises GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-2, and/or IL-21. In some alternatives, the at least one cytokine comprises IL/7, IL-15 and/or IL-21. In some alternatives, the at least one cytokine comprises IL-2, IL-15 and/or IL-21. In some alternatives, the said plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise at least one receptor that promotes, induces, contribute to or enhances engraftment fitness.
  • the at least one receptor that promotes, induces, contribute to or enhances engraftment fitness is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L. In some alternatives, the at least one receptor that promotes, induces, contribute to or enhances engraftment fitness is CD27, CD28 and/or CD62L. In some alternatives, the plurality of affinity selected CD8+ and/or CD4+ T-cells further comprises a vector having a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the vector further comprises a sequence encoding a spacer.
  • the spacer comprises an IgG4 hinge.
  • the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector.
  • the viral vector is a lentivirus vector.
  • the cell surface selectable marker encodes for a truncated epidermal growth factor receptor (EGFRt).
  • the ligand binding domain comprises an antibody, or a binding portion thereof. In some alternatives, the ligand binding domain comprises a single chain variable fragment (scFv), or a binding portion thereof. In some alternatives, the ligand binding domain comprises FMC63, or a binding portion thereof. In some alternatives, the ligand binding domain is specific for CD19. In some alternatives, at least one population comprises isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells. In some alternatives, at least one population comprises isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells.
  • the composition or product combination comprises the population of genetically modified T-cells, wherein the population of genetically modified T-cells comprises isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells. In some alternatives, the composition or product combination comprises the population of genetically modified T-cells, wherein the population of genetically modified T-cells comprises isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells. In some alternatives, the population comprises isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells and isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells mixed or co-administered in a 1:1 ratio.
  • a method of treating, inhibiting, or ameliorating a disease in a subject in need thereof comprises administering to the subject at least one composition or product combination.
  • the at least one composition or product combination comprises a pharmaceutical excipient and at least one population of genetically modified T-cells.
  • the at least one population of genetically modified T-cells comprises a plurality of affinity selected CD8+ and/or CD4+ T-cells, in the absence of, enriched over or isolated from CD8 ⁇ and/or CD4 ⁇ T-cells, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells have stimulated CD2, CD3, CD4 and/or CD28 receptors, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise a gene encoding a chimeric antigen receptor and a cell surface selectable marker and, wherein said plurality of affinity selected CD8+ and/or CD4+ T-cells have been re-stimulated with at least one cytokine.
  • the at least one cytokine comprises GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-2, and/or IL-21. In some alternatives, the at least one cytokine comprises IL/7, IL-15 and/or IL-21. In some alternatives, the at least one cytokine comprises IL-2, IL-15 and/or IL-21. In some alternatives, the said plurality of affinity selected CD8+ and/or CD4+ T-cells further comprise at least one receptor that promotes engraftment fitness.
  • the at least one receptor that promotes, induces, contribute to or enhances engraftment fitness is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L. In some alternatives, the at least one receptor that promotes, induces, contribute to or enhances engraftment fitness is CD27, CD28 and/or CD62L. In some alternatives, the plurality of affinity selected CD8+ and/or CD4+ T-cells further comprises a vector having a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the vector further comprises a sequence encoding a spacer.
  • the spacer comprises an IgG4 hinge.
  • the vector is a viral vector.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector.
  • the viral vector is a lentivirus vector.
  • the cell surface selectable marker encodes for a truncated epidermal growth factor receptor (EGFRt).
  • the ligand binding domain comprises an antibody, or a binding portion thereof. In some alternatives, the ligand binding domain comprises a single chain variable fragment (scFv), or a binding portion thereof. In some alternatives, the ligand binding domain comprises FMC63, or a binding portion thereof. In some alternatives, the ligand binding domain is specific for CD19. In some alternatives, at least one population comprises isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells. In some alternatives, at least one population comprises isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells.
  • the composition or product combination comprises the population of genetically modified T-cells, wherein the population of genetically modified T-cells comprises isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells. In some alternatives, the composition or product combination comprises the population of genetically modified T-cells, wherein the population of genetically modified T-cells comprises isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells. In some alternatives, the population comprises isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells and isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells mixed or co-administered in a 1:1 ratio.
  • the method comprises administering the composition or product combination, wherein the composition or product combination comprises at least one population, wherein the at least one population comprises isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells. In some alternatives, the method comprises administering the composition or product combination, wherein the composition or product combination comprises at least one population, wherein the at least one population comprises isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells.
  • the method comprises administering the composition or product combination, wherein the composition or product combination comprises at least one population, wherein the at least one population comprises isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells and isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells mixed or co-administered in a 1:1 ratio.
  • the method further comprises administering the composition or product combination, wherein the composition or product combination comprises at least one population, wherein the at least one population comprises isolated CD8+ T-cells in the absence of or enriched over CD4+ T-cells.
  • the method further comprises administering the composition or product combination, wherein the composition or product combination comprises at least one population, wherein the at least one population comprises isolated CD4+ T-cells in the absence of or enriched over CD8+ T-cells.
  • the subject is identified or selected to receive an anti-cancer therapy.
  • the method further comprises measuring or evaluating an inhibition of a disease.
  • the method further comprises providing said subject an additional anti-cancer therapy before, during, or after administration of the composition or product combination.
  • the composition or product combinations are administered to said subject by adoptive cell transfer.
  • the composition or product combinations are administered to said subject after said subject has received another form of anti-cancer therapy.
  • composition or product combinations are administered to said subject after said subject has received another form of anti-cancer therapy.
  • the subject is suffering from leukemia.
  • the subject has recurrent and/or chemotherapy refractory CD19+ childhood acute lymphoblastic leukemia (ALL).
  • the subject has recurrent and/or chemotherapy refractory CD19+ acute lymphoblastic leukemia (ALL).
  • ALL recurrent and/or chemotherapy refractory CD19+ acute lymphoblastic leukemia
  • the subject is suffering from an autoimmune disease.
  • the subject is suffering from a post-HSCT relapse.
  • the separating, enriching, or isolating of the CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, from a mixed population of T-cells is performed by affinity selection for T-cells having an epitope present on CD8 and/or CD4.
  • the separating, enriching, or isolating of the CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells from a mixed population of T-cells is performed by flow cytometry.
  • the separating, enriching, or isolating of the CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells from a mixed population of T-cells is performed by immuno-magnetic selection.
  • the genetically modified CD8+ expressing T-cells and/or CD4+ expressing T-cells comprise at least one receptor that promotes, induces, or contributes to engraftment fitness.
  • the at least one receptor that promotes, induces, or contributes to engraftment fitness is CD45 RA, CD45 RO, CCR7, CD25, CD127, CD57, CD137, CD27, CD28 and/or CD62L.
  • the at least one receptor that promotes, induces, or contributes to engraftment fitness is CD27, CD28 and/or CD62L.
  • the stimulating of the isolated, enriched, or separated population of T-cells is performed by contacting the CD8+ and/or CD4+ expressing T-cells with an antibody-bound support, such as a bead or particle.
  • the antibody-bound support comprises anti-TCR, anti-CD2, anti-CD3, anti-CD4 and/or anti-CD28 antibodies.
  • the antibody-bound support comprises anti-CD3 and/or anti-CD28 antibodies.
  • the vector further comprises a first sequence encoding a leader sequence, a second sequence encoding a ligand binding domain, a third sequence encoding a signaling domain and a fourth sequence encoding a selectable marker sequence.
  • the vector further comprises a sequence encoding a spacer, which in some alternatives may comprise an IgG4 hinge.
  • the vector is a viral vector or a mini-circle.
  • the viral vector is derived from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentivirus, or retroviruses.
  • the viral vector is a recombinant adenovirus, adeno-associated virus, lentivirus or retrovirus vector.
  • the viral vector is a lentivirus vector.
  • the marker sequence encodes a truncated epidermal growth factor receptor (EGFRt).
  • the at least one cytokine that is utilized comprises GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-15, IL-2, and/or IL-21 and said cytokine is provided exogenously to the T-cells e.g., in addition to any cytokine that may be produced by the cells or present in media.
  • the at least one cytokine comprises IL-7, IL-15 and/or IL-21. In many of the aforementioned alternatives, the at least one cytokine comprises IL-2, IL-15 and/or IL-21. In desirable alternatives, the at least one cytokine comprises IL-21 and another cytokine, and/or comprises IL-7 and at least one other cytokine, and/or comprises IL-15 and at least one other cytokine, such as comprising IL-21 and IL-15, comprising IL-21 and IL-7, or comprising IL-15 and IL-7, or comprising IL-2 and IL-15, or comprising IL-7 and IL-15.
  • the contacting period is performed for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or a period of time within a range defined by any two of these time points.
  • the methods are performed with isolated, separated, or enriched populations of CD4+ expressing T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, in the absence of or having a reduced amount CD8+ expressing T-cells, as compared to a native population of unseparated, non-enriched, or non-isolated population of T-cells.
  • these methods are performed with isolated, separated, or enriched populations of CD8+ expressing T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, in the absence of or having a reduced amount of CD4+ expressing T-cells, as compared to a native population of unseparated, non-enriched, or non-isolated population of T-cells.
  • isolated, separated, or enriched populations of CD8+ expressing T-cells such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, desirably iPS cells, in the absence of or having a reduced amount of CD4+ expressing T-cells, as compared to a native population of unseparated, non-enriched, or non-isolated population of T-cells.
  • the CD4+ expressing T-cells are propagated for at least 1 day, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or any time that is within a range of times defined by any two of the aforementioned time points.
  • the CD8+ expressing T-cells are propagated for at least 1 day, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or any time that is within a range of times defined by any two of the aforementioned time points.
  • a method of making genetically modified T-cells, which have a chimeric antigen receptor comprises separating or enriching a CD8+ expressing population of T-cells and/or a CD4+ expressing population of T-cells, such as T-cells that are derived from thymocytes or T-cells that are derived from engineered precursors, wherein the precursors are optionally iPS cells, from a mixed population of T-cells, so as to generate a separated or enriched population of T-cells, stimulating the separated or enriched population of T-cells so as to generate a stimulated population of CD8+ T-cells and/or CD4+ T-cells, transducing the stimulated population of CD8+ T-cells and/or CD4+ T-cells with a vector, wherein the vector encodes a chimeric antigen receptor so as to generate a transduced population of CD8+ T-cells and/or CD4+ T-cells
  • the method further comprises enriching the transduced, cytokine-stimulated population of CD8+ T-cells and/or CD4+ T-cells by selection of a marker, so as to generate an enriched population of transduced, cytokine-stimulated CD8+ T-cells and/or CD4+ T-cells.
  • the marker is encoded by the vector and optionally is a cell surface marker.
  • the method further comprises further comprising propagating the enriched population of transduced, cytokine-stimulated CD8+ T-cells and/or CD4+ T-cells for at least one day, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days or for a period that is within a range defined by any two of the aforementioned time periods.
  • a method of producing genetically modified T cells comprises introducing a vector encoding a recombinant protein into cells of a CD4+-enriched T cell composition, and incubating cells of the CD4+ enriched T cell composition with a combination of cytokines comprising IL-7 and IL-15, and/or introducing a vector encoding a recombinant protein into cells of a CD8+ enriched T cell composition and incubating cells of the CD8+ enriched T cell composition with a combination of cytokines comprising IL-2 and IL-15, wherein the method thereby generates a transduced CD4+ enriched population and/or a transduced CD8+ enriched population.
  • the transduced CD4+ enriched population has a higher level of surface expression of CD62L, CD27, and/or CD28, as compared to a reference enriched population of transduced CD4+ cells, and/or has an increased indicator of engraftment fitness and/or expansion, and/or persistence, upon administration to a subject as compared to the reference enriched population of transduced CD4+ cells, wherein the reference population is a CD4+-enriched population prepared by another method, which is identical to the method, except that the IL-2 alone is used in place of the combination of cytokines.
  • the transduced CD8+ enriched population has a higher level of surface expression of CD62L, CD27, and/or CD28, as compared to a reference enriched population of transduced CD8+ cells, and/or has an increased indicator of engraftment fitness and/or expansion, and/or persistence, upon administration to a subject as compared to the reference enriched population of transduced CD8+ cells, wherein the reference population is a population of CD8+-enriched cells prepared by another method that is identical to the method, except that the IL-2 alone is used in place of the combination of cytokines.
  • a method of producing genetically modified T cells comprises introducing a vector encoding a recombinant protein into cells of a CD4+ enriched T cell composition and incubating cells of the CD4+ enriched T cell composition with a first combination of cytokines and introducing a vector encoding a recombinant protein into cells of a CD8+ enriched T cell composition and incubating cells of the CD8+ enriched T cell composition with a second combination of cytokines which is distinct from the first combination of cytokines, wherein the method thereby generates a transduced CD4+ enriched population and a transduced CD8+ enriched population.
  • the transduced CD4+ enriched population has a higher level of surface expression of CD62L, CD27, and/or CD28, as compared to a reference enriched population of transduced CD4+ cells prepared by another method that is identical to the method, except that the first and second combination of cytokines are identical, and/or has an increased indicator of engraftment fitness and/or expansion, and/or persistence, upon administration to a subject as compared to the reference enriched population of transduced CD4+ cells.
  • the transduced CD8+ enriched population has a higher level of surface expression of CD62L, CD27, and/or CD28, as compared to a reference enriched population of transduced CD8+ cells prepared by another method that is identical to the method, except that the first and second combination of cytokines are identical, and/or has an increased indicator of engraftment fitness and/or expansion, and/or persistence, upon administration to a subject as compared to the reference enriched population of transduced CD8+ cells.
  • the first combination comprises IL-7 and IL-15 and the second combination comprises IL-2 and IL-15.
  • the cytokine combination(s) is added subsequently to transduction initiation, and optionally on the same day as transduction initiation.
  • the concentration of IL-2 is at or about 50 U/mL, where applicable, the concentration of IL-15 is at or about 0.5 ng/mL, where applicable, and/or the concentration of IL-7 is at or about 5 ng/mL, where applicable.
  • the addition of the combination of cytokines to the CD4+-enriched and/or to the CD8+-enriched composition comprises increasing the volume of the composition in which the cells are incubated, thereby decreasing cell density.
  • the indicator of engraftment fitness comprises a percentage of cells in the composition or total surface expression levels for the population of a cell surface marker selected from the group consisting of CD62L, CD27, and/or CD28.
  • the indicator of engraftment fitness comprises persistence in a subject upon administration.
  • the cells are derived from the subject.
  • transduced CD8+ and/or CD4+ cells persist upon administration to a subject from which the cells were derived, for at least at or about 30 or 60 days post injection of the cells into the subject.
  • the recombinant protein is a chimeric antigen receptor.
  • the method further comprises prior to the transduction, enriching a T cell composition for cells expressing CD4, thereby generating the enriched CD4+ enriched T cell composition so-transduced, and/or, prior to the transduction, enriching a T cell composition for cells expressing CD8, thereby generating the enriched CD8+ enriched T cell composition so-transduced.
  • the method further comprises cryopreserving the engineered cells.
  • the method further comprises administering the engineered cells to a subject, and optionally further comprising pooling the transduced CD4+ enriched and the transduced CD8+ enriched compositions prior to said administering.
  • a cell or composition is produced by any of the alternatives of the methods listed in the previous paragraphs of this section of more alternatives. In some alternatives, a method of administering the cell produced by any of the alternatives of the method or the alternatives of the compositions listed in the previous paragraphs is contemplated. In some alternatives, the cell or composition is administered to a subject. In some alternatives, the administration is to a subject from which the cells were derived.
  • a method of adoptive cell therapy comprises (a) incubating a CD4+-enriched T cell composition under stimulating conditions and in the presence of IL-15 and IL-7, thereby generating an expanded CD4+ composition, (b) separately incubating a CD8+-enriched T cell composition under stimulating conditions and in the presence of IL-15 and IL-2, thereby generating an expanded CD8+ composition, and (c) administering the expanded CD4+ and expanded CD8+ populations to a subject, optionally simultaneously.
  • the CD4+ and CD8+ populations are obtained from the subject.
  • the one or more of the recited cytokines or combinations of cytokines further comprises CD21.
  • the CD4+-enriched population or the total number of T cells therein comprises at least 70, 80, 90, 95, 96, 97, 98, or 99% CD4+ cells
  • the C8+-enriched population or the total number of T cells therein comprises at least 70, 80, 90, 95, 96, 97, 98, or 99% CD8+ cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
US15/302,426 2014-04-10 2015-04-08 Defined composition gene modified t-cell products Abandoned US20170015746A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/302,426 US20170015746A1 (en) 2014-04-10 2015-04-08 Defined composition gene modified t-cell products

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201461977751P 2014-04-10 2014-04-10
US201461986479P 2014-04-30 2014-04-30
US201462058973P 2014-10-02 2014-10-02
US201462088363P 2014-12-05 2014-12-05
US201462089730P 2014-12-09 2014-12-09
US201462090845P 2014-12-11 2014-12-11
PCT/US2015/024866 WO2015157384A1 (fr) 2014-04-10 2015-04-08 Produits à base de cellules t génétiquement modifiées à composition définie
US15/302,426 US20170015746A1 (en) 2014-04-10 2015-04-08 Defined composition gene modified t-cell products

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/024866 A-371-Of-International WO2015157384A1 (fr) 2014-04-10 2015-04-08 Produits à base de cellules t génétiquement modifiées à composition définie

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/660,114 Continuation US20220372140A1 (en) 2014-04-10 2022-04-21 Defined composition gene modified t-cell products

Publications (1)

Publication Number Publication Date
US20170015746A1 true US20170015746A1 (en) 2017-01-19

Family

ID=54288361

Family Applications (12)

Application Number Title Priority Date Filing Date
US15/302,426 Abandoned US20170015746A1 (en) 2014-04-10 2015-04-08 Defined composition gene modified t-cell products
US15/302,415 Active US10266592B2 (en) 2014-04-10 2015-04-08 Drug regulated transgene expression
US15/302,449 Abandoned US20170029774A1 (en) 2014-04-10 2015-04-08 Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
US15/302,403 Active US10865242B2 (en) 2014-04-10 2015-04-08 Method and compositions for cellular immunotherapy
US15/302,420 Active 2035-04-30 US10611837B2 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
US16/287,074 Active US11155616B2 (en) 2014-04-10 2019-02-27 Drug regulated transgene expression
US16/794,673 Active 2035-12-07 US11414486B2 (en) 2014-04-10 2020-02-19 Transgene genetic tags and methods of use
US17/096,138 Pending US20210139583A1 (en) 2014-04-10 2020-11-12 Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
US17/097,630 Pending US20210371517A1 (en) 2014-04-10 2020-11-13 Method and compositions for cellular immunotherapy
US17/472,284 Pending US20220064292A1 (en) 2014-04-10 2021-09-10 Drug regulated transgene expression
US17/660,114 Pending US20220372140A1 (en) 2014-04-10 2022-04-21 Defined composition gene modified t-cell products
US17/812,848 Pending US20220380461A1 (en) 2014-04-10 2022-07-15 Transgene genetic tags and methods of use

Family Applications After (11)

Application Number Title Priority Date Filing Date
US15/302,415 Active US10266592B2 (en) 2014-04-10 2015-04-08 Drug regulated transgene expression
US15/302,449 Abandoned US20170029774A1 (en) 2014-04-10 2015-04-08 Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
US15/302,403 Active US10865242B2 (en) 2014-04-10 2015-04-08 Method and compositions for cellular immunotherapy
US15/302,420 Active 2035-04-30 US10611837B2 (en) 2014-04-10 2015-04-08 Transgene genetic tags and methods of use
US16/287,074 Active US11155616B2 (en) 2014-04-10 2019-02-27 Drug regulated transgene expression
US16/794,673 Active 2035-12-07 US11414486B2 (en) 2014-04-10 2020-02-19 Transgene genetic tags and methods of use
US17/096,138 Pending US20210139583A1 (en) 2014-04-10 2020-11-12 Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
US17/097,630 Pending US20210371517A1 (en) 2014-04-10 2020-11-13 Method and compositions for cellular immunotherapy
US17/472,284 Pending US20220064292A1 (en) 2014-04-10 2021-09-10 Drug regulated transgene expression
US17/660,114 Pending US20220372140A1 (en) 2014-04-10 2022-04-21 Defined composition gene modified t-cell products
US17/812,848 Pending US20220380461A1 (en) 2014-04-10 2022-07-15 Transgene genetic tags and methods of use

Country Status (19)

Country Link
US (12) US20170015746A1 (fr)
EP (8) EP3129405B1 (fr)
JP (12) JP6765968B2 (fr)
KR (8) KR102509481B1 (fr)
CN (7) CN106661570B (fr)
AU (8) AU2015243922B2 (fr)
BR (3) BR112016023517A2 (fr)
CA (5) CA2945303C (fr)
ES (2) ES2880932T3 (fr)
IL (5) IL297591A (fr)
MX (6) MX2016013159A (fr)
MY (4) MY185678A (fr)
NZ (3) NZ725081A (fr)
PH (4) PH12016502011A1 (fr)
RU (5) RU2751920C2 (fr)
SA (1) SA516380056B1 (fr)
SG (8) SG10201808825XA (fr)
WO (5) WO2015157399A1 (fr)
ZA (2) ZA201607060B (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10494422B2 (en) 2014-04-29 2019-12-03 Seattle Children's Hospital CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
CN110662834A (zh) * 2017-05-26 2020-01-07 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
US10618959B2 (en) 2016-01-20 2020-04-14 Nbe-Therapeutics Ag ROR1 antibody compositions and related methods
US10758556B2 (en) 2017-08-07 2020-09-01 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
US20200297768A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020210023A1 (fr) * 2019-04-08 2020-10-15 Russell Biotech, Inc. Procédures de fabrication améliorées pour des thérapies basées sur des cellules
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
US11123369B2 (en) 2015-08-07 2021-09-21 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11161913B2 (en) 2018-08-30 2021-11-02 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US11759480B2 (en) 2017-02-28 2023-09-19 Endocyte, Inc. Compositions and methods for CAR T cell therapy
US11779602B2 (en) 2018-01-22 2023-10-10 Endocyte, Inc. Methods of use for CAR T cells
US11845793B2 (en) 2015-10-30 2023-12-19 Nbe-Therapeutics Ag Anti-ROR1 antibodies
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12121527B2 (en) 2017-08-07 2024-10-22 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548667C (zh) * 2003-01-20 2009-10-14 日本瑞翁株式会社 层合件及其制造方法
EP3858379A1 (fr) * 2013-11-21 2021-08-04 Autolus Limited Cellule
CN106459917B (zh) 2014-04-23 2021-03-09 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
CN117427091A (zh) 2014-10-20 2024-01-23 朱诺治疗学股份有限公司 用于过继细胞治疗中的给药的组合物和方法
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
US11266739B2 (en) 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
JP6892822B2 (ja) 2014-12-05 2021-06-23 メモリアル スローン ケタリング キャンサー センター Ｂ細胞成熟化抗原を標的化する抗体および使用の方法
CA3008162A1 (fr) 2014-12-15 2016-06-23 The Regents Of The University Of California Recepteur d'antigene chimere de type porte ou bispecifique sensible a cd19 et a cd20
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
WO2016115559A1 (fr) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Anticorps et récepteurs antigéniques chimériques spécifiques de ror1
AU2016222850B2 (en) * 2015-02-24 2021-04-01 Board Of Regents, The University Of Texas System Selection methods for genetically-modified T cells
KR102632082B1 (ko) 2015-02-27 2024-02-02 아이셀 진 테라퓨틱스 엘엘씨 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
KR20180021137A (ko) 2015-06-25 2018-02-28 아이셀 진 테라퓨틱스 엘엘씨 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법
CA2999608A1 (fr) * 2015-09-22 2017-03-30 Julius-Maximilians-Universitat Wurzburg Procede de transfert genique stable et de haut niveau dans des lymphocytes
ES2809550T3 (es) 2015-10-06 2021-03-04 Hope City Receptores de antígenos quiméricos dirigidos contra PSCA
AU2016341446A1 (en) * 2015-10-23 2018-05-24 Sanford Health Prognosis and treatment of squamous cell carcinomas
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
US11345926B2 (en) * 2015-12-14 2022-05-31 GenomeFrontier Therapeutics, Inc. Transposon system, kit comprising the same, and uses thereof
US20180371052A1 (en) * 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
EP3202783A1 (fr) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Cellules présentant des antigènes modifiés et leurs utilisations
US20190355459A1 (en) 2016-03-16 2019-11-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
WO2017190100A1 (fr) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Constructions d'acide nucléique permettant la co-expression d'un récepteur antigénique chimérique et d'un facteur de transcription, cellules les contenant et leur utilisation thérapeutique
EP3463396A1 (fr) * 2016-06-07 2019-04-10 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Récepteur d'antigène chimère et cellules t-car se liant à bcma
JP2019517267A (ja) * 2016-06-08 2019-06-24 イントレキソン コーポレーション Ｃｄ３３特異的キメラ抗原受容体
EP4353750A3 (fr) 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Récepteurs antigéniques chimériques (car), compositions et procédés associés
US20190119636A1 (en) * 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
AU2017343780B2 (en) 2016-10-13 2023-08-31 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US11739129B2 (en) * 2016-10-21 2023-08-29 Washington University AP4 and methods of promoting T cell activation
AU2017368248A1 (en) * 2016-11-30 2019-06-06 Intrexon Corporation Steroid administration and immunotherapy
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
CN106800601B (zh) * 2017-01-19 2021-04-06 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
CN110418802A (zh) * 2017-01-20 2019-11-05 朱诺治疗学有限公司 细胞表面缀合物及相关的细胞组合物和方法
US20200191774A1 (en) 2017-02-27 2020-06-18 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
BR112019019005A2 (pt) 2017-03-14 2020-04-14 Sara Elizabeth Church métodos para armazenagem criogênica
CN106963945A (zh) * 2017-03-27 2017-07-21 山东兴瑞生物科技有限公司 一种加强型人乳头瘤病毒hpv‑16/18的二价dc疫苗
WO2018191490A1 (fr) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Utilisation de l'édition génomique pour générer des lymphocytes t re-dirigés contre tcr universels pour une immunothérapie adoptive
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变系统及构建方法
CA3063695A1 (fr) * 2017-05-17 2018-11-22 Seattle Children's Hospital (Dba Seattle Children's Research Institute Generation de promoteurs synthetiques inductibles par activation de lymphocytes t mammiferes (syn + pro) pour ameliorer le traitement des lymphocytes t
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
EP3630132A1 (fr) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles de fabrication et procédés de traitement utilisant une thérapie cellulaire adoptive
CN107335054B (zh) * 2017-06-30 2021-01-15 山东兴瑞生物科技有限公司 一种慢性乙肝治疗性dc疫苗
CA3072569A1 (fr) * 2017-08-11 2019-02-14 Tribiotica Llc Procedes de generation d'epitopes pour la liaison a des molecules de reconnaissance par assemblage sur gabarit
CN111094349A (zh) * 2017-08-23 2020-05-01 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 嵌合抗原受体和结合cxcr5的car-t细胞
WO2019067504A1 (fr) * 2017-09-26 2019-04-04 Longwood University Récepteur d'antigène chimérique spécifique à pd-1 en tant qu'immunothérapie
WO2019079486A1 (fr) 2017-10-18 2019-04-25 Intrexon Corporation Compositions polypeptidiques comprenant des espaceurs
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR20200099132A (ko) * 2017-11-01 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 조작된 세포의 치료적 조성물을 생성하기 위한 프로세스
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019089969A2 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
EP3707160A1 (fr) 2017-11-10 2020-09-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Récepteurs d'antigènes chimériques ciblant des antigènes tumoraux
JP2021502829A (ja) 2017-11-14 2021-02-04 メモリアル スローン ケタリング キャンサー センター Ｉｌ−３６を分泌する免疫応答性細胞およびその使用
WO2019123340A1 (fr) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
PE20210640A1 (es) 2018-02-13 2021-03-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
CN108383914A (zh) * 2018-02-23 2018-08-10 北京美康基免生物科技有限公司 一种基于cd19的嵌合抗原受体及其应用
WO2019178613A1 (fr) * 2018-03-16 2019-09-19 Immusoft Corporation Lymphocytes b génétiquement modifiées pour sécréter de la follistatine et leurs méthodes d'utilisation pour traiter des maladies, des états, des troubles liés à la follistatine et pour améliorer la croissance et la résistance musculaires
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
EP3793565B1 (fr) 2018-05-14 2022-01-05 Gilead Sciences, Inc. Inhibiteurs mcl-1
WO2019219029A1 (fr) * 2018-05-15 2019-11-21 科济生物医药（上海）有限公司 Cellule génétiquement modifiée et application de cette dernière
WO2020003210A1 (fr) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anticorps anti-l1cam et leurs utilisations
ES2962674T3 (es) 2018-07-13 2024-03-20 Gilead Sciences Inc Inhibidores PD-1/PD-L1
CN110845621A (zh) * 2018-08-21 2020-02-28 上海恒润达生生物科技有限公司 一种靶向egfr和cd19双靶点的嵌合抗原受体方法
EP3844191A4 (fr) * 2018-08-31 2022-06-15 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Procédés et compositions comprenant des récepteurs antigéniques chimériques b7h3
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
AU2019372046B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
EP3873608A1 (fr) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
TW202031894A (zh) 2018-11-01 2020-09-01 中國大陸商亘喜生物科技（上海）有限公司 用於t細胞工程之組合物及方法
WO2020102770A1 (fr) * 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Méthodes de posologie pour cellules t modifiées pour le traitement de cancers à cellules b
SG11202105502RA (en) * 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
CA3120364A1 (fr) * 2018-11-30 2020-06-04 Celularity Inc. Cellules car-t allogeniques derivees de placenta et leurs utilisations
PT3886894T (pt) * 2018-11-30 2024-05-02 Juno Therapeutics Inc Métodos para dosagem e tratamento de malignidades de células b em terapia celular adotiva
AU2020231201A1 (en) 2019-03-07 2021-08-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (fr) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting
JP7350872B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチドおよびそのプロドラッグ
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof
CN109979545A (zh) * 2019-04-16 2019-07-05 北京中佰耀因医药科技有限公司 一种含样本状态信息管理模块的精准用药智能报告系统
CN109872792A (zh) * 2019-04-16 2019-06-11 北京中佰耀因医药科技有限公司 一种用于指导精准用药的基因检测智能报告系统
CN109994156A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含报告模板信息管理模块的精准用药智能报告系统
CN109994180A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含基因位点信息管理模块的精准用药智能报告系统
CN110010222A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基于精准用药知识库的基因身份识别系统
CN110010200A (zh) * 2019-04-16 2019-07-12 长沙三济生物科技有限公司 一种基因身份识别系统
CN109994176A (zh) * 2019-04-16 2019-07-09 北京中佰耀因医药科技有限公司 一种含样本类型信息管理模块的精准用药智能报告系统
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN114222763A (zh) * 2019-06-19 2022-03-22 尤利乌斯·马克西米利安维尔茨堡大学 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点
CA3142513A1 (fr) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Proteines de fusion flt3l-fc et procedes d'utilisation
CN110608991B (zh) * 2019-09-09 2022-04-29 浙江普罗亭健康科技有限公司 基于质谱流式检测技术的细胞周期检测试剂盒及检测方法
CN114555123B (zh) 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
AU2020374947A1 (en) 2019-10-31 2022-03-31 Forty Seven, Inc. Anti-CD47 and anti-CD20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11845723B2 (en) 2019-12-24 2023-12-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN111533808B (zh) * 2020-03-10 2021-02-09 南京医科大学 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用
KR20220156041A (ko) 2020-03-20 2022-11-24 라이엘 이뮤노파마, 인크. 신규 재조합 세포 표면 마커
MX2022013619A (es) 2020-05-01 2022-11-16 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina que inhiben cd73.
CN115701999A (zh) * 2020-07-09 2023-02-14 南京传奇生物科技有限公司 用白介素-36工程化γδT细胞用于免疫疗法
CA3188656A1 (fr) 2020-07-17 2022-01-20 Simurx, Inc. Recepteurs myd88 chimeriques pour rediriger une signalisation immunosuppressive, compositions et procedes associes
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022155526A2 (fr) * 2021-01-15 2022-07-21 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Protéines de cellules immunitaires hybrides et tronquées
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2022271659A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2022271677A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
JP2024532305A (ja) * 2021-08-24 2024-09-05 賽斯尓▲チン▼生物技術（上海）有限公司 細胞を修飾する方法
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
CN118139858A (zh) 2021-10-28 2024-06-04 吉利德科学公司 吡地嗪-3(2h)-酮衍生物
KR20240097895A (ko) 2021-10-29 2024-06-27 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
CA3239528A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de degradation de doigt de zinc de la famille ikaros et utilisations associees
CA3237577A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de degradation des doigts de zinc de la famille ikaros et leurs utilisations
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023173137A1 (fr) * 2022-03-11 2023-09-14 Yale University Compositions et méthodes de modification génétique efficace et stable de cellules eucaryotes
AU2023233730A1 (en) 2022-03-17 2024-09-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023187031A1 (fr) * 2022-04-01 2023-10-05 Miltenyi Biotec B.V. & Co. KG Système pour l'expression inductible par médicament d'un polynucléotide
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
WO2023212691A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
WO2023227900A1 (fr) * 2022-05-27 2023-11-30 Autolus Limited Procédé
AR129552A1 (es) * 2022-06-10 2024-09-04 Joint Stock Company “Biocad” Ácido nucleico con actividad promotora y uso del mismo
WO2024006702A1 (fr) * 2022-06-27 2024-01-04 Foundation Medicine, Inc. Procédés et systèmes pour prédire des appels génotypiques à partir d'images de diapositives entières
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
CN116179495A (zh) * 2022-11-28 2023-05-30 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
WO2024129984A1 (fr) * 2022-12-15 2024-06-20 The Board Of Trustees Of The Leland Stanford Junior University Insertion d'adn ciblée indépendante de l'homologie dans des lymphocytes t humains
WO2024137652A2 (fr) * 2022-12-20 2024-06-27 Abata Therapeutics, Inc. Thérapies cellulaires pour le diabète de type 1
WO2024137852A1 (fr) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
CN118359729A (zh) * 2023-01-19 2024-07-19 武汉昭智生物技术有限公司 一种car分子、包含其的细胞或外泌体及它们的应用
CN116844685B (zh) * 2023-07-03 2024-04-12 广州默锐医药科技有限公司 一种免疫治疗效果评估方法、装置、电子设备及存储介质

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226901A1 (en) * 2009-02-18 2010-09-09 Califorina Institute Of Technology Genetic control of mammalian cells with synthetic rna regulatory systems
US20130287748A1 (en) * 2010-12-09 2013-10-31 The Trustees Of The University Of Pennsylvania Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer
US20140112956A1 (en) * 2011-04-13 2014-04-24 Immunicum Ab Method for Proliferation of Antigen-Specific T Cells
US20150038694A1 (en) * 2012-02-20 2015-02-05 Xenus Srl Glucose derivatives bound to arsenic for use in the treatment of tumour
US20150299656A1 (en) * 2012-09-06 2015-10-22 The United States of America, as represented by th Secretary, Department of Health and Human Service Methods of producing t memory stem cell populations

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69128037T2 (de) 1990-11-13 1998-05-07 Immunex Corp., Seattle, Wash. Bifunktionelle wählbare fusionsgene
US20020111474A1 (en) 1990-12-14 2002-08-15 Capon Daniel J. Chimeric chains for receptor-associated signal transduction pathways
JPH07507278A (ja) 1992-06-01 1995-08-10 ニューイングランド　メディカル　センター　ホスピタルズ　インク Ｃｄ４３キメラ分子による細胞間相互作用の阻害
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US6660257B1 (en) * 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
AU2472400A (en) * 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6912492B1 (en) * 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
JP4045713B2 (ja) 2000-01-31 2008-02-13 松下電器産業株式会社 自動機用溶接機
GB0015119D0 (en) * 2000-06-20 2000-08-09 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
CA2413156C (fr) * 2000-07-03 2009-08-18 Gala Design, Inc. Vecteurs d'expression
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
EP1334188B1 (fr) 2000-11-07 2006-08-30 City of Hope Cellules immunitaires specifiques a cd19 redirigees
MXPA03008031A (es) 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
US7070995B2 (en) * 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097099A1 (fr) 2001-05-29 2002-12-05 Valentis, Inc. Expression regulee de somatostatine
WO2003025228A1 (fr) * 2001-09-18 2003-03-27 Proteologics, Inc. Procede et composition permettant de traiter des affections en lien avec la proteine hcap
US20030148982A1 (en) * 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
US20030228606A1 (en) 2002-04-11 2003-12-11 Amgen Inc., A Corporation Of The State Of Delaware Her-2 receptor tyrosine kinase molecules and uses thereof
WO2004029284A2 (fr) 2002-09-30 2004-04-08 Protein Design Labs, Inc. Generation efficace de lignees cellulaires d'expression stable par utilisation de genes rapporteurs homeostatiques pouvant etre soumis a notation
AU2004213053C1 (en) * 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2004092338A2 (fr) 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, variants d'epissage et procedes concernant des genes et des proteines specifiques du cancer
CN1809277A (zh) * 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的移植物耐受
WO2005017102A2 (fr) 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, variants d'epissage et procedes associes a des acides nucleiques et des proteines specifiques
EP1649020B1 (fr) * 2003-07-21 2017-01-11 MSD Italia S.r.l. Gene synthetique codant l'antigene du facteur de croissance epidermique humain 2/neu et utilisations de celui-ci
US20070087346A1 (en) * 2003-10-24 2007-04-19 Gennaro Ciliberto Orthogonal gene switches
WO2005062881A2 (fr) 2003-12-24 2005-07-14 Transgenrx, Inc. Therapie genique faisant intervenir des vecteurs de transposon
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
DE202005002921U1 (de) 2005-02-23 2005-04-21 Magcode Ag Verbindungssystem, insbesondere elektrisches Verbindungssystem
CN101212977A (zh) * 2005-06-01 2008-07-02 国际创新生物技术研究所有限公司 葡萄糖可诱导的胰岛素表达和治疗糖尿病的方法
CN101511994A (zh) 2006-05-22 2009-08-19 海普罗塞尔有限公司 使用真核细胞系生成蛋白质
WO2008012237A1 (fr) * 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Construction de multiples antigènes et leur utilisation
US7709253B2 (en) * 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
WO2009013359A2 (fr) 2007-07-25 2009-01-29 Fraunhofer Gesellschaft Zur Förderung Der Angewandten Forschung E. V. Protéines de fusion d'anticorps recombinantes à auto-couplage
DK2279253T3 (en) * 2008-04-09 2017-02-13 Maxcyte Inc Construction and application of therapeutic compositions of freshly isolated cells
JP2012501180A (ja) 2008-08-26 2012-01-19 シティ・オブ・ホープ Ｔ細胞の抗腫瘍エフェクター機能増進のための方法および組成物
JP5771147B2 (ja) 2008-09-26 2015-08-26 トカジェン インコーポレーテッド 遺伝子治療ベクターおよびシトシンデアミナーゼ
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
WO2010141543A1 (fr) 2009-06-02 2010-12-09 Targeted Molecular Diagnostics, Llc Procédés de détection et de détermination quantitative de la composante p95 de her2/neu (erbb2)
US9873035B2 (en) * 2009-07-09 2018-01-23 Cfph, Llc Amusement device for a game of chance involving one or more rolling indicators on a rotating element with position indicators
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
JP5956342B2 (ja) * 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
JP5285678B2 (ja) 2010-06-18 2013-09-11 株式会社エヌ・ティ・ティ・ドコモ 移動通信方法及びコアネットワーク装置
PT3012268T (pt) * 2010-09-08 2018-01-31 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Recetores de antigénio quimérico com uma região de charneira otimizada
BR112013018311A2 (pt) 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
MX359513B (es) * 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2012167192A2 (fr) 2011-06-01 2012-12-06 Precision Biosciences, Inc. Procédés et produits pour la production de lignées cellulaires génétiquement modifiées de mammifère par des transgènes amplifiés
US20130011394A1 (en) 2011-06-22 2013-01-10 Hoffmann-La Roche Inc. Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use
CN109485730A (zh) 2011-10-20 2019-03-19 美国卫生和人力服务部 抗cd22嵌合抗原受体
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
WO2013074916A1 (fr) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Lymphocytes t car+ génétiquement modifiés pour éliminer l'expression du récepteur des lymphocytes t et/ou le système hla
ES2774160T3 (es) 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
CA2864688C (fr) * 2012-02-22 2023-09-05 The Trustees Of The University Of Pennsylvania Utilisation de recepteurs d'antigene chimeriques (car) comportant un costimulateur inductible (icos) afin d'ameliorer l'activite antitumoraleet la persistance des car
US9765342B2 (en) 2012-04-11 2017-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2013177533A1 (fr) 2012-05-25 2013-11-28 California Institute Of Technology Expression de polypeptides secrétés et de surface cellulaire
KR20150027756A (ko) 2012-05-30 2015-03-12 베일러 칼리지 오브 메디신 Dna 수복, 변경 및 대체를 위한 도구로서의 초나선 미니벡터
EP2669378A1 (fr) 2012-05-31 2013-12-04 Helmut Hanenberg Système de gène suicide du cytochrome P450
US9792559B2 (en) 2012-06-01 2017-10-17 Nec Corporation Switching system, line card, switch card, FDB learning method, FDB learning arbitration method and program
RS61345B1 (sr) 2012-08-20 2021-02-26 Hutchinson Fred Cancer Res Postupak i kompozicije za ćelijsku imunoterapiju
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
EP2964753B1 (fr) 2013-03-07 2018-04-25 Baylor College of Medicine Ciblage de cd138 dans le cancer
EP2777711A1 (fr) 2013-03-11 2014-09-17 Icon Genetics GmbH Vaccin contre le cancer her2/neu
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
WO2014186469A2 (fr) * 2013-05-14 2014-11-20 Board Of Regents, The University Of Texas System Application à des humains de lymphocytes t comprenant un récepteur antigénique chimérique (car)
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3063175A4 (fr) 2013-10-31 2017-06-21 Fred Hutchinson Cancer Research Center Cellules effectrices non t, progénitrices et souches hématopoïétiques modifiées, et leurs utilisations
EP3858379A1 (fr) 2013-11-21 2021-08-04 Autolus Limited Cellule
CN107074957B (zh) 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
SG10201808825XA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Defined composition gene modified t-cell products
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
IL287889B2 (en) 2016-02-05 2024-03-01 Hope City Administration of transgenic T cells for the treatment of central nervous system cancer
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US10714296B2 (en) 2018-12-12 2020-07-14 Axcelis Technologies, Inc. Ion source with tailored extraction shape

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226901A1 (en) * 2009-02-18 2010-09-09 Califorina Institute Of Technology Genetic control of mammalian cells with synthetic rna regulatory systems
US20130287748A1 (en) * 2010-12-09 2013-10-31 The Trustees Of The University Of Pennsylvania Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer
US20140112956A1 (en) * 2011-04-13 2014-04-24 Immunicum Ab Method for Proliferation of Antigen-Specific T Cells
US20150038694A1 (en) * 2012-02-20 2015-02-05 Xenus Srl Glucose derivatives bound to arsenic for use in the treatment of tumour
US20150299656A1 (en) * 2012-09-06 2015-10-22 The United States of America, as represented by th Secretary, Department of Health and Human Service Methods of producing t memory stem cell populations

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865242B2 (en) 2014-04-10 2020-12-15 Seattle Children's Hospital Method and compositions for cellular immunotherapy
US11414486B2 (en) 2014-04-10 2022-08-16 Seattle Children's Hospital Transgene genetic tags and methods of use
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
US11155616B2 (en) 2014-04-10 2021-10-26 Seattle Children's Hospital Drug regulated transgene expression
US10494422B2 (en) 2014-04-29 2019-12-03 Seattle Children's Hospital CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11123369B2 (en) 2015-08-07 2021-09-21 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11845793B2 (en) 2015-10-30 2023-12-19 Nbe-Therapeutics Ag Anti-ROR1 antibodies
US11242388B2 (en) 2016-01-20 2022-02-08 Nbe-Therapeutics Ag ROR1 antibody compositions and related methods
US10618959B2 (en) 2016-01-20 2020-04-14 Nbe-Therapeutics Ag ROR1 antibody compositions and related methods
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
US11759480B2 (en) 2017-02-28 2023-09-19 Endocyte, Inc. Compositions and methods for CAR T cell therapy
CN110662834A (zh) * 2017-05-26 2020-01-07 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
US12121527B2 (en) 2017-08-07 2024-10-22 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
US10758556B2 (en) 2017-08-07 2020-09-01 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US11779602B2 (en) 2018-01-22 2023-10-10 Endocyte, Inc. Methods of use for CAR T cells
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US11161913B2 (en) 2018-08-30 2021-11-02 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
US20200297768A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020210023A1 (fr) * 2019-04-08 2020-10-15 Russell Biotech, Inc. Procédures de fabrication améliorées pour des thérapies basées sur des cellules
US20220195414A1 (en) * 2019-04-08 2022-06-23 Russell Biotech, Inc. Improved Manufacturing Procedures for Cell Based Therapies
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer

Also Published As

Publication number Publication date
MX2016013158A (es) 2017-04-27
JP2017515464A (ja) 2017-06-15
KR20160144432A (ko) 2016-12-16
CA2945303C (fr) 2024-02-13
CN113528581A (zh) 2021-10-22
RU2751920C2 (ru) 2021-07-20
JP2020195380A (ja) 2020-12-10
MY185678A (en) 2021-05-30
NZ725079A (en) 2018-03-23
CA2945305C (fr) 2023-10-17
RU2016143385A (ru) 2018-05-15
KR20230038310A (ko) 2023-03-17
NZ725081A (en) 2018-02-23
BR112016023507A2 (pt) 2017-10-17
US11414486B2 (en) 2022-08-16
AU2021201679B2 (en) 2023-05-04
JP7542270B2 (ja) 2024-08-30
RU2016143384A (ru) 2018-05-11
US10266592B2 (en) 2019-04-23
SG10201808833XA (en) 2018-11-29
IL248238B1 (en) 2024-10-01
EP3129480A4 (fr) 2017-08-16
WO2015157432A1 (fr) 2015-10-15
US20220380461A1 (en) 2022-12-01
AU2021200007A1 (en) 2021-03-04
BR112016023500A2 (pt) 2017-10-17
MX2016013159A (es) 2017-04-27
AU2021200007B2 (en) 2024-08-29
CN112877291A (zh) 2021-06-01
AU2015243849A9 (en) 2019-07-25
EP3129399A4 (fr) 2017-11-08
JP2021019589A (ja) 2021-02-18
BR112016023517A2 (pt) 2017-10-17
EP3129405A4 (fr) 2017-08-09
WO2015157391A1 (fr) 2015-10-15
IL297591A (en) 2022-12-01
SG10201808811QA (en) 2018-11-29
AU2015243927B2 (en) 2021-09-02
EP3129471A1 (fr) 2017-02-15
CA2945320A1 (fr) 2015-10-15
EP3129405A1 (fr) 2017-02-15
ZA201607061B (en) 2024-05-30
RU2016143385A3 (fr) 2018-11-30
AU2015243922A1 (en) 2016-11-03
CN106573969A (zh) 2017-04-19
MX2016013160A (es) 2017-02-09
RU2752275C2 (ru) 2021-07-26
AU2015243920B2 (en) 2020-10-08
KR102618955B9 (ko) 2024-08-12
CN106574246A (zh) 2017-04-19
JP2021036867A (ja) 2021-03-11
IL248243B1 (en) 2023-12-01
SG10201808825XA (en) 2018-11-29
US20220064292A1 (en) 2022-03-03
KR102508166B1 (ko) 2023-03-13
CN106536558A (zh) 2017-03-22
BR112016023523A2 (pt) 2017-10-17
RU2016143389A (ru) 2018-05-15
ES2880932T3 (es) 2021-11-26
SG11201608392WA (en) 2016-11-29
PH12016502009A1 (en) 2017-01-09
AU2015243922B2 (en) 2021-08-05
JP2017513470A (ja) 2017-06-01
IL248229A (en) 2016-11-30
IL248229B1 (en) 2023-01-01
WO2015157399A9 (fr) 2016-11-24
KR102463529B1 (ko) 2022-11-07
KR20160143762A (ko) 2016-12-14
RU2016143381A3 (fr) 2018-11-30
JP2022184989A (ja) 2022-12-13
KR102387243B9 (ko) 2023-07-10
KR102600544B1 (ko) 2023-11-09
AU2021273652A1 (en) 2021-12-16
CN106661570A (zh) 2017-05-10
JP2017518037A (ja) 2017-07-06
IL248243A0 (en) 2016-11-30
CA2945308C (fr) 2023-10-31
EP3943507A1 (fr) 2022-01-26
RU2016143389A3 (fr) 2018-12-04
KR20220051024A (ko) 2022-04-25
CN106535934A (zh) 2017-03-22
US20220372140A1 (en) 2022-11-24
SG11201608395PA (en) 2016-11-29
BR112016023500B1 (pt) 2024-04-30
JP2022153456A (ja) 2022-10-12
PH12016502010A1 (en) 2017-01-09
RU2729112C2 (ru) 2020-08-04
JP2017513520A (ja) 2017-06-01
CA2945303A1 (fr) 2015-10-15
CN106661570A8 (zh) 2017-07-04
JP6788573B2 (ja) 2020-11-25
IL248235B (en) 2021-01-31
EP3129399A1 (fr) 2017-02-15
WO2015157399A1 (fr) 2015-10-15
JP7062720B2 (ja) 2022-05-06
AU2015243927A1 (en) 2016-11-03
RU2016143381A (ru) 2018-05-11
AU2015243882A1 (en) 2016-11-03
US11155616B2 (en) 2021-10-26
CA2945302A1 (fr) 2015-10-15
JP7093385B2 (ja) 2022-06-29
JP2021000117A (ja) 2021-01-07
JP6765968B2 (ja) 2020-10-07
AU2021201679A1 (en) 2021-04-08
AU2015243882C1 (en) 2024-07-25
PH12016502011A1 (en) 2017-01-09
MX2016013149A (es) 2017-04-27
JP6788573B6 (ja) 2020-12-16
AU2015243882B2 (en) 2020-03-12
RU2016143388A (ru) 2018-05-14
NZ758289A (en) 2024-01-26
US20210139583A1 (en) 2021-05-13
EP3129471A4 (fr) 2017-11-08
EP3129405B1 (fr) 2021-02-24
KR102387243B1 (ko) 2022-04-14
JP6772068B2 (ja) 2020-10-21
US20180009891A1 (en) 2018-01-11
JP7402933B2 (ja) 2023-12-21
KR20160144430A (ko) 2016-12-16
WO2015157386A1 (fr) 2015-10-15
KR102463529B9 (ko) 2024-07-31
IL248243B2 (en) 2024-04-01
MY186846A (en) 2021-08-26
IL248235A0 (en) 2016-11-30
MY184163A (en) 2021-03-24
CN106661570B (zh) 2020-02-07
EP3129399B1 (fr) 2021-05-26
MY192522A (en) 2022-08-25
US10865242B2 (en) 2020-12-15
EP3129480A1 (fr) 2017-02-15
US20190248891A1 (en) 2019-08-15
EP4056201A1 (fr) 2022-09-14
CA2945308A1 (fr) 2015-10-15
US20210002364A1 (en) 2021-01-07
EP3129053A4 (fr) 2017-11-08
MX2022010807A (es) 2022-09-27
AU2015243920A1 (en) 2016-11-03
JP2017512484A (ja) 2017-05-25
JP7148580B2 (ja) 2022-10-05
AU2015243849B2 (en) 2020-12-17
IL248238A0 (en) 2016-11-30
KR102618955B1 (ko) 2023-12-27
US20170029774A1 (en) 2017-02-02
US20170267742A1 (en) 2017-09-21
KR102509481B1 (ko) 2023-03-10
SG11201608396YA (en) 2016-11-29
PH12016502012A1 (en) 2017-01-09
RU2751921C2 (ru) 2021-07-20
KR20160138298A (ko) 2016-12-02
BR112016023513A2 (pt) 2017-10-17
KR20160144431A (ko) 2016-12-16
IL248229B2 (en) 2023-05-01
ES2867224T3 (es) 2021-10-20
SG10201808819XA (en) 2018-11-29
KR20220153100A (ko) 2022-11-17
EP3954708A1 (fr) 2022-02-16
JP2022109953A (ja) 2022-07-28
NZ739448A (en) 2019-10-25
SA516380056B1 (ar) 2021-07-04
SG11201608393TA (en) 2016-11-29
ZA201607060B (en) 2024-05-30
JP7106610B2 (ja) 2022-07-26
WO2015157384A1 (fr) 2015-10-15
JP6765967B2 (ja) 2020-10-14
US20210371517A1 (en) 2021-12-02
RU2016143384A3 (fr) 2018-11-30
AU2015243849A1 (en) 2016-11-03
RU2016143388A3 (fr) 2018-11-30
US10611837B2 (en) 2020-04-07
CA2945305A1 (fr) 2015-10-15
JP7508516B2 (ja) 2024-07-01
EP3129053A1 (fr) 2017-02-15
MX2016013144A (es) 2017-04-27
CN106573969B (zh) 2021-07-30
US20170152297A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
AU2021200007B2 (en) Defined composition gene modified T-cell products
AU2018270156B2 (en) Generating mammalian T cell activation inducible synthetic promoters (syn+pro) to improve T cell therapy
TW202134264A (zh) 嵌合抗原受體及其用途
JP2021534783A (ja) キメラ抗原受容体発現細胞を作製する方法
JP2023516008A (ja) キメラ抗原受容体発現細胞を作製する方法
WO2021148019A1 (fr) Méthode de transduction de cellules avec un vecteur viral
US20220195441A1 (en) Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
AU2019234580B2 (en) IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy
US20230374104A1 (en) Methods and compositions comprising pd1 chimeric polypeptides
TW202300643A (zh) 用於增強幹細胞樣記憶ｔ細胞工程改造之材料及方法
WO2023172514A1 (fr) Agents thérapeutiques de cellules immunitaires modifiés ciblés sur her2 et leurs procédés d'utilisation

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

AS Assignment

Owner name: SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JENSEN, MICHAEL C;REEL/FRAME:048715/0316

Effective date: 20190326

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION